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Abstract
The bidirectional relationship between the gut microbiome and immune system plays an
important role in host immune status: the immune system provides the gut microbiome
the optimal environment to thrive in, and the gut microbiome helps regulate the immune
system. This relationship is especially important in infants, whose immune system is still
premature and rely on innate immunity.

We investigated the three-way interplay among early-life exposures, the developing gut
microbiome, and outcomes in infancy from the general population in New Hampshire,
US. We used prospective cohort data from the New Hampshire Birth Cohort study to 1)
determine whether timing of baby rice cereal introduction is related to respiratory
infections, symptoms, and allergy in infancy; 2) identify gut microbiome composition
and bacterial species that may influence respiratory infections and symptoms; 3) identify
bacterial species and metabolic pathways that associate with antibody response to
pneumococcal capsular polysaccharide and tetanus toxoid vaccination; and 4) develop a
statistical approach to test the mediating effect of the microbiome on the “causal” path
between exposure and outcome. Our studies highlight the potential to modulate the infant
gut microbiome to improve health outcomes in infancy.
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Chapter 1: General Introduction
1.1 Early life exposures and immune-related outcomes in infancy
Infections and allergy remain a leading cause of morbidity and mortality in the US. In
additional to the physical burden on infants as a result of these outcomes are the side
effects from treatment and long-term effects, and the substantial economic impacts1,2.
There are several factors associated with infants’ susceptibility to disease. Prenatal
exposures, breast feeding status, and diet can all contribute to an infant’s risk of
developing an infection3–7 or allergy8–10. Antibiotic use, including prenatal, peripartum,
and prenatal exposures, can also influence risks11–16.

Accumulating evidence indicates that contaminants in our environment, which may come
through our diet, also affect our immunity to disease17,18. Arsenic, a widespread toxicant,
has been shown to have adverse effects on human health through the life course. Rice
grown in the United States is an important source of exposure to arsenic19. In particular,
infants, including the U.S., commonly transition to solid food with rice cereal20. As a
result, infants who have been fed rice products have high concentrations of urinary
arsenic21. Arsenic exposure has been associated with impaired immune response and
increased risk of infections and chronic diseases22. Previous research on in utero arsenic
exposure found increase in maternal urinary arsenic associated with increased risk of
infection and respiratory symptoms in the first year of infant life23. Findings of elevated
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arsenic levels among infants consuming rice products24 have raised concerns that rice
cereal consumption may have detrimental effects on infant health. Exploring the health
impacts of early life rice cereal exposure could elucidate this issue, but to date, very little
research has been done on this.

1.2 Gut microbiome and immunity
The bidirectional relationship between the gut microbiome and immunity evolves
following birth; the gut microbiome aids in the maturation of the early immune system
while the immune system regulates host-microbe symbiosis25,26. While neonates rely on
innate immunity to protect against pathogens, the both the innate and the adaptive
immune systems co-evolve over time with the maturation of intestinal epithelial cells 27.
The relationship between gut microbiome composition and immune response has been
largely studied in mice models. Colonization of Clostridia-related Segmented
Filamentous Bacterium induces innate and adaptive T cell28,29 and IgA response in
mice30,31. Clostridium-abundant mice also demonstrate higher T-regs and lower IgE
levels compared to control mice32. Bacterial symbionts, such as Bifidobacterium
adolescentis, found in the human gut, trigger Th17 cells induction and accumulation in
mice33,34. Both Bacteroides fragilis and Faecalibacterium prausnitzii species increase
CD4T cells that produce IL-1035–37. Lactobacillus reuteri has shown to induce doublepositive intraepithelial T lymphocytes38, which aid in the prevention of inflammatory
bowel disease39. Studies also have shown the gut microbiome to regulate hematopoiesis
that can control host bacterial infection40
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A growing body of research has linked human gut microbiome to a variety of health
outcomes including inflammatory bowel disease and metabolic diseases in humans 41.
Much of this work has focused on adults, whereas far less is known on the effect of earlylife gut microbiome composition on infant outcomes. The work, thus far, provides
evidence of possible associations between infant gut microbiome and diseases such as
type I diabetes, allergy, and necrotizing enterocolitis, with associations lasting into
childhood and adulthood42. The infant gut microbiome has also been linked to child
allergy and atopy43, and there are data suggesting that modulating the gut microbiome
could reduce risk44–46. The link between the early gut microbiome and respiratory
infections47,48 and vaccine response49–52 in infancy, while plausible, is not understood.

1.3 Gut microbiome as a mediator between exposures and outcomes
The driving factors associated with adverse health outcomes in early life also shape the
developing gut microbiome in early life, including delivery mode, diet, and antibiotic
use42,53. Experimentally, the microbiome can modify contaminants54. In both laboratory
and epidemiologic studies, arsenic may impact the gut microbiome, and in vitro
undergoes pre-systemic metabolism to compounds with greater toxic potential 55.

Mediation analyses is becoming popular in microbiome research to elucidate the
contribution of the infant gut microbiome on the relationship between an exposures or
treatments and downstream health outcomes. Studies now suggest that a healthy gut
microbiome, possibly with probiotic supplementation, may prevent infection-related
outcomes such as necrotizing enterocolitis and late-onset sepsis associated with preterm
3

birth 56. The infant gut microbiome also may mediate the possible beneficial effect of
farm exposure on school-age asthma57. Similarly, one study found that the infant gut
microbiome mediated in the association between maternal pre-pregnancy overweight
status and child overweight status between the ages of 1 and 3 years58. Mice and human
studies also both suggest that the early gut microbiome may mediate the adverse effect of
antibiotic exposure on later disease59–61.

1.4 Statistical methods analyzing microbiome as a mediator
The primary approach to examining mediating mechanisms is through the classical threestep method for mediation analysis 62. While several approaches exist to mediation
analyses, the main ones in the literature are structured equation models 63,64 and the
causal inference-based approach predicated on counterfactuals with a single mediator 65–
67

. Methods for evaluating multiple mediators are beginning to emerge 68,69, including

those to incorporate high dimensional mediators 70–81. Modelling the microbiome is
especially challenging due to the high-dimensional, compositional, and zero-inflated
nature of microbiome data. Methods for microbiome mediation analysis include those
examining the microbiome as a whole or those identifying specific mediating taxa82–88.
However, few existing limited methods can account for exposure-mediator interactions
and multiple types of outcomes (continuous and dichotomous).

1.5 Thesis Aims
This thesis aims to understand the three-way interplay among early-life exposures, the
infant gut microbiome, and outcomes in infancy. We first investigated the association
4

between timing of rice cereal introduction and respiratory infections, respiratory
symptoms, and allergy in a general population cohort of maternal-infant dyads. We then
examined the association between the infant gut microbiome at 6 weeks of life and
outcomes including respiratory infections, respiratory symptoms, wheeze, diarrhea, and
vaccine response to PCP and TT in early childhood. Finally, we proposed a novel
hypothesis test for microbiome mediation that accounts for the high dimensional and
compositional nature of microbiome data and dichotomous outcomes.
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Chapter 2: Infant infections, respiratory symptoms, and allergy in
relation to timing of rice cereal introduction in a United States
cohort

Published as Moroishi, Y., Signes-Pastor, A.J., Li, Z. et al. Infant infections, respiratory
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2.1 Abstract

Rice products marketed in the USA, including baby rice cereal, contain inorganic arsenic,
a putative immunotoxin. We sought to determine whether the timing of introduction of
rice cereal in the first year of life influences occurrence of infections, respiratory
symptoms, and allergy. Among 572 infants from the New Hampshire Birth Cohort Study,
we used generalized estimating equation, adjusted for maternal smoking during
pregnancy, marital status, education attainment, pre-pregnancy body mass index,
maternal age at enrollment, infant birth weight, and breastfeeding history. Among 572
infants, each month earlier of introduction to rice cereal was associated with increased
risks of subsequent upper respiratory tract infections (relative risk, RR = 1.04; 95% CI:
1.00–1.09); lower respiratory tract infections (RR = 1.19; 95% CI: 1.02–1.39); acute
respiratory symptoms including wheeze, difficulty breathing, and cough (RR = 1.10; 95%
CI: 1.00–1.22); fever requiring a prescription medicine (RR = 1.22; 95% CI: 1.02–1.45)
and allergy diagnosed by a physician (RR = 1.20; 95% CI: 1.06–1.36). No clear
associations were observed with gastrointestinal symptoms. Our findings suggest that
introduction of rice cereal earlier may influence infants’ susceptibility to respiratory
infections and allergy.

2.2 Introduction

Early life is a critical period of immune system development and impacts health
lifelong89,90. Infections remain the leading causes of mortality in children under five years
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of age around the world91. Feeding practices, in particular breast feeding, are known to
protect against infections and improve child health outcomes7; however, far less is known
about the impact of diet during infants’ transition to solid foods. Rice is an important
dietary source of arsenic, including rice products commonly fed to infants as a first food
and as snacks92,19,93,94. In flooded rice paddy fields, rice grains accumulate arsenic at rates
about 10 times higher than that of other grains19,95,96. Additionally, arsenicals such as
monosodium methanearsonate and disodium methanearsonate were used in pesticides
and herbicides. Although these compounds are now mostly banned, residues remain in
soil95,97,98. While rice cereal fortified with iron may be a good source of nutrients,
concerns have been raised about this practice because of the arsenic content of rice-based
products99. In previous studies from our cohort, infant urinary arsenic concentrations
increased with consumption of rice products during infants transition to solid food24, and
at one year of age, infants fed rice products had elevated urinary concentrations of arsenic
compared to those who were not fed these products21.

Exposure to arsenic early in life has been specifically associated with an impaired
immune response and increased risk of infection 22,100,101. Infants are especially
vulnerable to respiratory infections, in part due to their immature immune system 102.
Studies have reported associations between in utero arsenic exposure and a number of
adverse outcomes including infant infections and respiratory outcomes among highly
exposed populations in Bangladesh and among US infants 23,103,104. These findings are
supported by mechanistic evidence that in utero arsenic exposure may influence the
epigenome of the placenta105, immune cell profiles in newborn cord blood106, and the
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infant gut microbiome107. While epidemiologic data are lacking on allergy outcomes,
maternal urinary arsenic concentrations during pregnancy were related to higher activated
Th2 cells, which produce cytokines responsible for IgE production, a marker of allergic
response108–111. In addition, there is evidence that early arsenic exposure influences
childhood infections risk in highly exposed populations112,113.

Despite health concerns114,115, a regulatory limit for arsenic in infant rice cereal has not
yet ratified in the USA. The European Union (EU) established a standard for inorganic
arsenic in infant rice products to a maximum level of 100 µg/kg116. The US Food and
Drug Administration (FDA) proposed the same guidance for infant rice cereal in 2016117.
In 2018, the Governmental Accountability Office recommended that the FDA and US
Department of Agriculture coordinate their efforts to identify contaminants in food
including arsenic and establish a timeline for finalizing the guidance118. An action level
has been set by the FDA for apple juice, but not other foods119. In 2006, the USA set the
maximum contaminant level for inorganic arsenic in drinking water to be 10 µg/L120, but
evidence on the detrimental health impacts at even lower levels of exposure led to the
reduction of the drinking water standard in certain states, including New Jersey121 and
New Hampshire122, to 5 µg/L. In light of the vulnerability of infants to early life
environmental exposures, we investigated the timing of introduction of rice cereal during
their transition to solid food in first year of life and subsequent risk of infections,
immune-related symptoms, and allergies as part of the New Hampshire Birth Cohort
Study (NHBCS).

9

2.3 Methods
2.3.1 Study Design
Participants in this study include mother-infant dyads from the NHBCS. Pregnant women
aged 18 to 45, receiving prenatal care at study clinics in New Hampshire, USA, were
recruited starting in January 2009 as described previously123,124. The cohort includes only
women who were living in the same household since their last menstrual period, not
planning to move, living in a household served by a private water system, and with a
singleton pregnancy. Participants completed surveys, including questions on
sociodemographic factors, lifestyle such as smoking history, and pre-pregnancy body
mass index (BMI), and infant birth characteristics were ascertained from a review of the
delivery medical records. Home tap water samples were collected and analyzed by
inductively coupled mass spectrometry to detect arsenic species125. The Committee for
the Protection of Human Subjects at Dartmouth College approved all protocols, and
participants provided written informed consent upon enrollment. All methods were
performed in accordance with relevant guidelines and regulations.

2.3.2 Data Collection
Telephone interviews were conducted with caregivers when the infants turned 4, 8, and
12 months of age and at 6-month intervals thereafter. The survey asked whether or not
their infant ever consumed rice cereal from birth and the day of the telephone interview
(yes/no) and the month (or age in months) that rice cereal was introduced to their diet.
Caregivers were asked whether their child had any infections, acute respiratory symptoms
(e.g., wheeze, difficulty breathing, and cough), diarrhea or fever since the last time they
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were interviewed. For positive responses, participants were asked to report if the
condition lasted for more than 2 days, if the child saw a doctor, and if the child received
prescription medicine for the condition. Participants were further asked whether their
child had any known allergy (e.g., cats or dogs, antibiotics, dust, grass and plants, pollen,
insect bites, peanuts, other nuts, eggs, and other foods), and for positive responses, if the
allergy was diagnosed by a doctor.

2.3.3 Statistical Analysis
We examined rice cereal intake prior to the occurrence of infection. Specifically, we
examined months since first introduction of rice cereal by 4 months of age on 8-month
outcomes, months since first introduction of rice cereal by 8 months of age on 12-month
outcomes, and months since first introduction of rice cereal by 12 months of age on 18month outcomes. For example, we examined number of months since rice cereal
consumption of a subject at 8 months, on occurrence of health outcome at 12months,
which is the subsequent survey collection interval. For each interval (i.e., 4, 8, or 12
months), we computed the number of months since rice cereal was introduced and
included an indicator variable of whether rice cereal was consumed in that interval
(yes/no). We multiplied this indicator variable by number of months since rice cereal was
introduced as our main predictor.

We then used Generalized Estimating Equation (GEE) with Poisson regression with
AR(1) correlation structure and robust variance to assess the association between months
since introduction of rice cereal exposures and repeated measures of longitudinal
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outcomes126. Factors associated with both rice exposure, as determined from our data
(Supplementary Table 2.7), and outcomes, considered a priori and used in previous
studies23, were considered potential confounders and included in our models. These
included smoking during pregnancy (yes/no), maternal relationship status (married,
single, separated/divorced), maternal education (≤ high school/GED, some college,
college graduate, postgraduate schooling), maternal pre-pregnancy BMI, maternal age of
enrollment (years), infant birth weight (grams), breastfeeding status as of four months
(ever/never), and consumption of other solid food than rice cereal (ever/never) at each
time point. Because water can be used to make rice cereal and is also a surrogate for in
utero arsenic exposure, we also adjusted for total arsenic concentrations measured in
household tap water samples (µg/L) in our analyses. For interpretability, we
exponentiated the coefficient values to obtain relative risk (RR) and 95% confidence
intervals (CI). Of the 572 participants included in the analyses, 482 participants (84.3%)
had complete data for at least one time interval on rice cereal consumption and on
subsequent health outcomes along with all potentially confounding variables considered.
For the other 90 participants, we assumed for the values for potential confounders were
missing at random using multiple imputation by chained equations and the predictive
mean matching method to impute missing data127. All analyses were performed using R
version 3.4.3 and functions mice and geeglm in packages ‘mice’ and ‘geepack’.

2.4 Results
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2.4.1 Baseline Characteristics
Of the 1760 pregnancies enrolled in the NHBCS as of October 2017, a total of 983
infants had complete follow-up data up to at least age of 8 months. After removing
missing values on rice cereal consumption (54 missing) and subsequent health outcome
information (357 missing), the final dataset contained 572 infants (Supplementary Figure
2.1). We found that the characteristics of the 411 subjects excluded from our analyses
were generally similar to that of included subjects, with the exception of marital status
(Supplementary Table 2.1). Our study group included a roughly equal distribution of
male (54%) and female (46%) infants (Table 2.1). Among infants who were introduced to
rice cereal in the first year of life, the average age at introduction was 5.2 months (SD:
1.3 months) (Supplementary Table 2.2). At the 4 month, 8 month, and 12 month time
periods, rice cereal was consumed in 11.7%, 69.6%, and 68.6% of infants respectively
(Supplementary Table 2.2). Overall, 96.5% of infants were reporting as having at least
one infection or symptom of any duration reported up to age 18 months, 91.4% having at
least one lasting 2 or more days, 65.2% having at least one involving a doctor’s visit, and
52.3% having at least one resulting in a prescription medication (Supplementary Table
2.2). For allergies, 13.5% of infants were reporting as having at least one allergy, and
7.9% having at least one diagnosed by a doctor (Supplementary Table 2.2). Sample sizes
and proportions of each outcome for each follow-up interval are reported in
Supplementary Table 2.3. Household tap water arsenic concentrations were generally
low, with a mean 2.2 µg/L (SD: 7.1; range: 0.0 to 92.3), but with 11.1% of the study
population having levels above the New Hampshire drinking water standard of 5 µg/L
(Table 2.1).
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Table 2. 1: Selected Characteristics of Mothers and Infants (N = 572) in the New
Hampshire Birth Cohort Study Followed to Age 18 Months
Variable
Maternal Characteristics
Smoking during any trimester of pregnancy,
No. (%)
Yes
No
Relationship status, No. (%)
Married
Single
Separated/Divorced
Highest level of educational attainment, No.
(%)
≤high school/GED
Some college
College graduate
Postgraduate schooling
BMI before pregnancy (kg/m2), mean (SD)
Age at enrollment (years), mean (SD)
Arsenic in water (µg/L), mean (SD)
Water Arsenic > 5 µg/L, No. (%)
Infant Characteristics
Sex, No. (%)
Male
Female
Birth weight (g), mean (SD)
Ever breast fed at 4 months, No. (%)
Yes
No
Other solid food consumption at 4 months,
No. (%) b
Yes
No
Other solid food consumption at 8 months,
No. (%) b
Yes
No
Other solid food consumption at 12 months,
No. (%) b
Yes

Sample Size

Mean (SD) or No.
(%)

552
61 (11.1)
491 (88.9)
538
486 (90.3)
43 (8.0)
9 (1.7)
537

560
572
552
552

52 (9.7)a
90 (16.8)a
214 (39.9)a
181(33.7)a
26.1 (5.7)
31.9 (4.8)
2.2 (7.1)
61 (11.1)

572
555
537

310 (54.2)
262 (45.8)
3416.7 (522.8)
513 (95.5)
24 (4.5)

358
14 (3.9)
344 (96.1)
437
120 (27.5)
317 (72.5)
544
137 (25.2)
14

No

407 (74.8)

Abbreviations: SD, standard deviation; No., number; BMI, body mass index.
Of the 572 participants included in the analyses, 482 participants (84.3%) had data at least one timeperiod of rice cereal consumption, health outcome data for a subsequent time period, and complete
data on confounders. Smoking during pregnancy was missing for 20 (3.50%) mothers, relationship
status was missing for 34 (5.94%) mothers, education was missing for 35 (6.12%) mothers, and prepregnancy BMI was missing for 12 (2.10%) mothers. Birth weight was missing for 17 (2.97%) and
breast-feeding status was missing for 59 (10.31%) infants. Other solid food consumption at 8 months
was missing for 1 (0.23%) infant. A total of 20 (3.50%) participants had missing data for arsenic
species in water.
a
Percentages do not sum to 100 due to rounding
b
Percentage calculated using different sample sizes due to missing values. Sample sizes were 321,
373, and 464 for 4 months, 8 months, and 12 months respectively.

2.4.2 Rice Cereal and Infections, Respiratory Symptoms, and Allergy
In our GEE analysis, earlier introduction of rice cereal was associated with increased
risks of lower respiratory tract infections (i.e. bronchitis, pneumonia, bronchiolitis,
whooping cough, and respiratory syncytial virus), respiratory symptoms, fever, and
allergies, and to a lesser extent upper respiratory tract infections (i.e. runny stuffed nose,
eye infection, ear infection, severe flu, sinus infection, strep throat, and laryngitis), but
not gastrointestinal symptoms (Figure 2.1). While the magnitudes of the associations did
not differ greatly across the variables for a given outcome and the confidence intervals
overlapped, there was a tendency for the risk ratios to be higher for outcomes involving a
health care provider visit or a medication prescribed (Figure 2.1, Supplementary Table
2.4). Relative risk estimates for upper and lower respiratory tract infections requiring a
prescription medicine increased by 4% (RR = 1.04; 95% CI: 1.00-1.09) and by 19%
(RR=1.19; 95% CI: 1.02-1.39) for each month earlier that rice cereal was introduced. A
10% increase in the relative risk of acute respiratory symptoms requiring a prescription
medicine (RR = 1.10; 95% CI: 1.00-1.22) and 22% increase of fever symptoms requiring
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prescription medicine (RR = 1.22; 95% CI: 1.02-1.45) were observed for each month
earlier that rice cereal was introduced. For reported allergies diagnosed by a doctor, the
relative risk estimate was 20% higher for each month earlier that rice cereal was
introduced (RR = 1.20; 95% CI: 1.06-1.36), and for this outcome, the relative risk
estimate was similar to any reported allergy. We did not observe any consistent
associations with diarrhea, including symptoms requiring a doctor’s visit (RR = 0.89; CI,
0.74-1.06). Only three cases of diarrhea had a medication prescribed, so this outcome was
not included in the GEE analysis. Risk ratio estimates and confidence intervals for
covariates included in our models are provided in Supplementary Table 2.5. Results for
crude analyses are provided in Supplementary Table 2.6.
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Figure 2. 1: Adjusted Risk Ratios (95% CIs) for Each Month Earlier of Introduction of
Rice Cereal According to Outcome Severity, N = 572 infants.
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Abbreviations: RR risk ratio.
RR indicates risk ratio for health outcomes according to reported severity. The circles indicate RR at
each severity level for each outcome. The lines indicate the 95% confidence intervals. The grey line
represents the null RR=1. Number of total outcome cases in three repeated measures is denoted by n.
Number of observed outcomes can be higher due to repeated events among time points for each infant.
Sample size N = 571 for fever analyses.

2.5 Discussion
In our prospective cohort study, we found that earlier introduction of rice cereal to an
infant’s diet was associated with higher risks of both upper and lower respiratory tract
infections, respiratory symptoms, fever, and allergies. These associations were slightly
stronger for what may have been more severe outcomes of lower respiratory tract
infection, respiratory symptoms, and fever, i.e., those characterized by having a
medication prescribed.

Infections remain the most important cause of morbidity in young children, and allergic
and atopy diseases are becoming more widespread91. In the USA, an estimated 42.8% of
infant hospitalizations in 2003 were due to infections128. Of these, 59.0% were due to
lower respiratory tract infections and 6.5% to upper respiratory tract infections128. In
2013, the Centers for Disease Control and Prevention (CDC) noted an increasing trend in
childhood food and skin allergies from 1997 to 2011129. In a 2017 CDC survey, 13% of
children under the age of 18 years had been told they had asthma, 11% a respiratory
allergy, 6.5% a food allergy, and 13.5% a skin allergy130. Thus, efforts to reduce infection
and allergy prevalence in infants is of critical public health importance.
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Early feeding practices play a critical role in the developing immune system of infants7,
but there are limited studies of the impact of infants’ transition to solid foods. In a large
prospective study from Dundee, Scotland (N = 545), early introduction of solid food was
related to an increased risk of infant wheeze, but not other respiratory illnesses131. One
prospective cohort study from the United Kingdom found infant introduction to solid
foods before 4 months of age was associated with higher odds of any diarrhea compared
to those introduced after 4 months of age (N = 615)132. Introduction of wheat after 6
months of age compared to before or equal to 6 months of age was associated with a
reduced risk of wheat allergies in a longitudinal birth cohort from Denver (N = 1612)133.
While research linking infant rice cereal exposure to later health outcomes is lacking, our
results align with previous studies that observed increased risks of infection with arsenic
exposure in early childhood. A Bangladeshi cohort study of children aged 7- 17 years
who were exposed to high levels of arsenic in utero and early childhood from
contaminated drinking water and sex- and age-matched controls without such exposures
observed increased respiratory symptoms such as wheezing and shortness of breath (N =
650) in the high arsenic exposure group112. In a separate case control study from
Bangladesh of children aged 28 days to 59 months who were hospitalized with severe and
very severe pneumonia and age-matched controls, the odds of pneumonia were elevated
among children with higher urinary arsenic concentrations measured both during
hospitalization and at the convalescent period (30 days after) (N = 449)113. Other cohort
studies from Bangladesh and from the USA have also associated childhood infections and
diarrhea in relation to in utero arsenic exposure23,103,104.
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Rice products are a well-recognized route of exposure to arsenic. Arsenic exposure has
been shown to increase risk of infections and other diseases, and emerging evidence
points to the toxicological effects of arsenic on immune function22,134. The World Health
Organization established a guideline for arsenic in drinking water of 10 µg/L in 1993 and
had acknowledged arsenic contamination in rice and rice products as a public health
concern135,136. In a 2014 EU report, concentrations of inorganic arsenic ranged from 56
µg/kg to 268 µg/kg for infant rice products137. A similar report from the USA covering
2012 to 2016 reported inorganic arsenic concentrations ranging from 21 µg/kg to 151
µg/kg for infant white rice cereal and from 30 µg/kg to 254 µg/kg for infant brown rice
cereal 138. In our cohort, 80% of infants were introduced to rice cereal in the first year of
life, and more than half of our infants were eating rice products at one year of age21.
Further, urinary arsenic concentrations increased with the number of rice and rice product
servings21. The American Academy of Pediatrics has raised awareness about arsenic
exposure from feeding infant rice products and recommends feeding infants a variety of
foods with a variety of textures94,139.

Our study has a number of strengths, but also has limitations that need to be noted. Our
study benefitted from the availability of prospective cohort data of carefully collected
repeated measurements of infection occurrences, respiratory symptoms, diarrhea, and
allergies; timing of introduction of rice cereal; and a broad range of potential
confounding factors. Among our main limitations was our inability to quantify the
concentrations of arsenic to which infants were exposed through rice cereal. This is in
part because the concentrations of arsenic in rice depends on a number of factors
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including genotype, cultivation, and irrigation techniques, and concentration can be
altered by cooking techniques140,141. Despite the heterogeneity of arsenic concentrations
in rice, we previously found rice cereal to be a contributor to arsenic exposure among our
infants 24. In our analyses, we also adjusted for household water arsenic concentration
along with indicator variables for breastfeeding and consumption of other solid foods.
Participant recall is a potential source of bias. Efforts to minimize non-differential
misclassification were made by including questions on duration of the illness and asking
whether the infant saw a doctor or was prescribed medicine for their condition. Stronger
associations were found with outcomes involving medical care, which would be expected
to have higher validity and reflect greater severity of illness. Furthermore, self-reporting
of allergies that were not medically confirmed was another potential source of
misclassification. We have found that responses from caregiver responses for infections
and symptoms that involved a doctor visit in our cohort tend to be at least 80%
concordant with their pediatric medical records (unpublished data). Our findings of an
increased risk of any reported diarrhea associated with earlier introduction rice
consumption should thus be interpreted with caution as the relative risk estimates were
not consistently elevated for diarrhea lasting 2 or more days or associated with a doctor’s
visit. The possibility of unmeasured confounding also cannot be excluded; however, we
assessed the potential confounding of factors previously found to be related to our
outcomes of interest and found that certain factors such as family history of allergy, day
care attendance, and parity were not associated with timing of rice cereal introduction.
The price of rice cereal in our cohort may be indicative of socio-economic status.
Although we did control for maternal marital status and highest level of education
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attainment, residual confounding remains a possibility. We inspected the costs of infant
cereals from five major grocery stores in a region of the state where recruitment took
place. We did not find that the costs of infant rice-based cereal products differed
appreciably from that of other grain cereals. Lastly, we computed 95% confidence
intervals for our analyses, which do not account for multiple comparisons.

In conclusion, our findings suggest that earlier introduction of rice cereal may increase an
infant’s risk of infections, respiratory symptoms, and allergies. The widespread
occurrence of these outcomes in young children and use of rice cereal as a first food
underscores the importance of considering the types and timing of foods introduced when
providing dietary recommendations for infants.
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3.1 Abstract
Emerging evidence points to a critical role of the developing gut microbiome in immune
maturation and infant health; however, prospective studies are lacking. We examined the
occurrence of infections and associated symptoms during the first year of life in relation
to the infant gut microbiome at six weeks of age using bacterial 16S rRNA V4-V5 gene
sequencing (N = 465) and shotgun metagenomics (N = 185). Higher infant gut
microbiota alpha diversity was associated with an increased risk of infections or
respiratory symptoms treated with a prescription medicine, and specifically upper
respiratory tract infections. Among vaginally delivered infants, a higher alpha diversity
was associated with an increased risk of all-cause wheezing treated with a prescription
medicine and diarrhea involving a visit to a health care provider. Positive associations
were specifically observed with Veillonella species among all deliveries and
Haemophilus influenzae among cesarean-delivered infants. Our findings suggest that
intestinal microbial diversity and the relative abundance of key taxa in early infancy may
influence susceptibility to respiratory infection, wheezing, and diarrhea.

3.2 Introduction
Infections remain the leading causes of mortality in infants globally142. The human gut
microbiome is becoming increasingly recognized for its critical role in immune function
and the inflammatory response47,143. A bidirectional relationship emerges following birth
whereby the gut microbiome aids the maturation of the immune system and the immune
system regulates host-microbe symbiosis25,26. The impacts of perturbing these intricate
relationships are evident in high-risk infants. For example, among infants with cystic
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fibrosis, the composition of the gut microbiome is a determinant of colonization with
opportunistic pathobionts144,145. Likewise, in preterm infants, the gut microbiome is
associated with fatal occurrences of necrotizing enterocolitis and infection143,146,147.
Factors driving the establishment of the gut microbiome, including delivery mode and
breast feeding47,124,148–150, have also been related to the risk of infections3,4,47,151–153.
Furthermore, the use of antibiotics during pregnancy, which has been found to influence
the gut microbiome of offspring154–156, increased the risk of infant infection-related
hospitalizations15. Encouraging results from probiotic trials suggest health benefits from
altering the gut microbiome, including an enhanced immune response to pathogens157,158.
While studies have found possible links between early gut microbiome composition and
infant infection47,159, few prospective studies have been conducted, particularly in the
general population.

We report on gut microbiome diversity and composition among infants during the critical
period of early immune training and the subsequent occurrence of respiratory infections
and symptoms, such as wheezing and diarrhea, in the first year of life as part of a
prospective study of a cohort of pregnant women and their offspring from the general
population in New Hampshire. Here, we measured the fecal microbiome to measure the
gut microbiome. Wheeze and diarrhea outcomes for this study included those of any
cause. Based on amplicon sequence variant (ASV) data generated from 16S rRNA
sequencing, higher alpha diversity at six weeks of age was associated with having an
additional respiratory infection or symptom of respiratory infection requiring a
prescription medicine, with associations varying by delivery mode. Using next-
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generation sequencing (NGS), shotgun metagenomics, Veillonella in all deliveries and
Haemophilus in cesarean deliveries were among the species in six-week stool identified
as being related to an additional subsequent respiratory infection or symptom of
respiratory infection requiring a prescription medicine during an infant’s first year of life.

3.3 Methods
3.3.1 Study Population
Participants included mother-infant dyads from the NHBCS from whom we obtained
infant stool samples at approximately six weeks of age. Pregnant women aged 18 to 45
were recruited from prenatal clinics in New Hampshire, USA, starting in January 2009,
as described previously123. Women who were living in the same household served by a
private water system since their last menstrual period, had no plans to move, and had a
singleton pregnancy were included in the cohort. Participants completed surveys on
infant lifestyle questions such as feeding mode, solid food introduction, and daycare.
Infant birth characteristics were ascertained from newborn medical records, and maternal
characteristics were abstracted from prenatal and delivery records, including age at
enrollment, prenatal use of antibiotics, and prepregnancy body mass index in kilograms
per meter squared. The Committee for the Protection of Human Subjects at Dartmouth
College approved all protocols, and participants provided written informed consent upon
enrollment.

3.3.2 Ascertainment of Infant Health Outcomes
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Telephone interviews were conducted with infants’ caregivers in the first year of life, i.e.,
when infants turned approximately 4 months, 8 months, and 12 months of age.
Caregivers were asked whether their child had any upper RTIs or associated symptoms
(e.g., runny nose, stuffy nose, eye infection, ear infection, influenza, sinus infection,
pharyngitis, or laryngitis), lower RTIs (e.g., bronchitis, pneumonia, bronchiolitis
(including respiratory syncytial virus (RSV)), or whooping cough), acute respiratory
symptoms (e.g., difficulty breathing, wheezing, fever, or cough), or diarrhea since the
previous interview. For each positive response, participants were then asked whether the
condition lasted more than 2 days, whether the child saw a physician, and whether the
child received any prescription medications for the condition.

3.3.3 Stool Sample Collection, DNA Extraction, Sequencing, and Profiling
We measured the fecal microbiome of infant stool as a measure of the infant gut
microbiome. Infant stool samples were collected at regularly scheduled ~6-week
postpartum follow-up appointments as described previously124,160. Samples were
aliquoted and frozen at -80 oC within 24 hours of receipt. A Zymo DNA extraction kit
(Zymo Research) was used for DNA extraction from thawed samples, and an OD260/280
nanodrop was used to measure sample quality and purity. The V4-V5 hypervariable
region of the bacterial 16S rRNA gene was sequenced using Illumina MiSeq at the
Marine Biological Laboratory in Woods Hole, Massachusetts. ASVs were then inferred
using DADA2161, and taxonomies were assigned using the SILVA database162. Quality
control measures were conducted as described previously124. A subset of stool samples
was also sequenced with NGS and shotgun metagenomics sequencing as previously
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described156. Extracted DNA samples were sheared to a mean insert size of 400 bp using
a Covaris S220 focused ultrasonicator. The sequencing libraries were constructed using
Nugen’s Ovation Ultralow V2 protocol, and samples were sequenced using Illumina
NextSeq. DNA reads were merged and trimmed using KneadData163 for quality control
before species-level taxonomic profiles were generated using Metaphlan2164.

3.3.4 Statistical Analysis
We examined the association between gut microbiome composition and health outcomes
ascertained during interval interviews over the subjects’ first year of life. For our
analyses, we examined the total number of reported outcomes, specifically upper RTIs
and lower RTIs, as well as symptoms such as wheezing with a reported visit to a
physician and treatment with a prescription medication. Diarrhea is not typically treated
with prescription medications in infants; therefore, we focused the analyses on reports of
diarrhea that involved a doctor visit. We imputed missing outcomes if the caregiver
completed the interview but a specific question was unanswered using multiple
imputation by chained equations and the predictive mean matching method.
For models using 16S data, we aggregated ASVs to the genus level and calculated
alpha diversity on read counts per genus using the inverse Simpson index. We then used a
GEE for repeated measures with Poisson regression and AR(1) correlation structure to
assess the association between log2-transformed 16S-based genus-level alpha diversity
and each of the outcomes of interest. For models using metagenomics species data, we
calculated the log2-transformed relative abundance using a pseudocount of 5x10-20 for
zero values. We also used a GEE for repeated measures with Poisson regression and
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AR(1) correlation structure to estimate relationships with species present in at least 10%
of subjects. We applied an FDR threshold of 0.1 to adjust for multiple testing165. Factors
associated with both the gut microbiome and health outcomes were considered potential
confounders and included in all GEE analyses. These confounders included maternal
prepregnancy BMI (kg/m2), delivery mode (vaginal/cesarean), infant sex (male/female),
breast feeding at six weeks (exclusively breastfed/mixed fed or exclusively formula fed),
antibiotic use during pregnancy (yes/no), and gestational age (complete weeks). We also
conducted stratified analyses by delivery type for both alpha diversity using 16S data and
microbial species based on metagenomics data. Due to sample size limitations, we
conducted stratified analyses only for species-specific analyses on all outcomes combined
and for upper RTIs.
For interpretability, we exponentiated the coefficient values to obtain relative risk
(RR) and 95% confidence intervals (CIs). Of the 465 participants included in the 16S
analyses, 391 participants (84.1%) had complete data for all potentially confounding
variables. Of the 185 participants included in the metagenomics analyses, 160
participants (86.5%) had complete data for all potentially confounding variables. We
assumed missing confounder entries were missing at random and used multiple
imputation by chained equations and the predictive mean matching method to impute
missing data. All analyses were performed using R version 3.4.3 using the functions
diversity, mice, and geeglm in the ‘vegan’, ‘mice’, and ‘geepack’ packages.
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3.4 Results
3.4.1 Baseline Characteristics
As of July 2019, we had completed 16S rRNA V4-V5 hypervariable region gene
sequencing on 513 infant stool samples and whole-genome metagenomics sequencing on
202 infant stool samples collected at approximately six weeks of age. After removing
infants for whom health information was unavailable in telephone surveys, our analysis
included 465 infants with 16S data and 185 infants with metagenomics data. Our study
population had an approximately equal distribution of male (53.4%) and female infants
(46.6%) (Table 3.1). Nearly half of the infants (56.2%) had been exclusively breastfed at
approximately six weeks of age, and approximately one-fifth of mothers (18.5%) had
reported antibiotic use during pregnancy (Table 3.1). Cesarean section deliveries
accounted for one-third of deliveries (30.3%) (Table 3.1). The five most common genera
in our 16S data were Escherichia/Shigella, Bacteroides, Bifidobacterium, Klebsiella, and
Enterococcus (Supplementary Figure 3.1). The five most common species in our
metagenomics data were Bifidobacterium longum, unclassified Escherichia species,
Escherichia coli, Bifidobacterium breve, and Gemella haemolysans (Supplementary
Figure 3.1). The numbers of each respiratory infection and symptom at each age are
provided in Supplementary Table 3.1 and Supplementary Table 3.2.
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Table 3. 1: Selected Baseline Characteristics of Mothers and Infants in the New
Hampshire Birth Cohort Study
Abbreviations: SD, standard deviation; No., frequency; kg, kilograms; m, meters.

Variable
Maternal Characteristics
Age at enrollment, mean
(SD), years
Body Mass Index before
pregnancy, mean (SD),
kg/m2
Parity, No. (%)
0
1
2+
Antibiotic use during
pregnancy, No. (%)
Yes
No
Infant Characteristics
Delivery mode, No. (%)
Vaginal
Cesarean
Infant sex, No. (%)
Male
Female
Breast feeding at six
weeks, No. (%)
Exclusively breast
fed
Mixed fed or
exclusive formula fed
Gestational age, Mean
(SD), weeks

16S V4-V5 rRNA
Sample Size
Mean (SD)
or No. (%)

Metagenomics
Sample Size Mean (SD)
or No. (%)

465

31.9 (4.6)

185

31.9 (4.3)

462

25.8 (5.9)

185

25.7 (5.7)

461

184
217 (47.1)
166 (36.0)
78 (16.9)

427

92 (50.0)
60 (32.6)
32 (17.4)
173

79 (18.5)
348 (81.5)
465

36 (20.8)
137 (79.2)
185

339 (72.9)
126 (27.1)
464

129 (69.7)
56 (30.3)
185

248 (53.4)
216 (46.6)
427

465

107 (57.8)
78 (42.2)
171

240 (56.2)

92 (53.8)

187(43.7)

79 (46.2)

39.1 (1.6)

185

39.0 (1.7)

Of the 465 mothers included in the 16S analyses, maternal BMI was missing for 3 mothers. Parity was
missing for 4 mothers, and antibiotic use during pregnancy was missing for 38 mothers.
Of the 465 infants included in the 16S analyses, infant sex was missing for 1 infant, and feeding type
was missing for 38 infants. Of the 185 mothers included in the metagenomics analyses, parity was
missing for 1 mother, and antibiotic use during pregnancy was missing for 12 mothers. Of the 185
infants included in the metagenomics analyses, feeding type was missing for 14 infants.
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3.4.2 16S V4-V5 rRNA Gene: Alpha Diversity
Associations were determined via the Wald test in generalized estimating equation (GEE)
analyses with a p-value threshold of 0.05. Alpha diversity was positively associated with
the occurrence of any respiratory infection or symptom of infection, which included
upper respiratory tract infections (RTIs), lower RTIs, and acute respiratory symptoms.
Upper RTI outcomes were specifically associated. Each doubling in alpha diversity was
associated with a 39% increase in having an additional respiratory infection or symptom
of respiratory infection (RR = 1.39, 95% CI: 1.1-1.77) and a 40% increase in an
additional upper RTI (RR = 1.40, 95% CI: 1.12-1.76) (Figure 3.1, Supplementary Table
3.3). Among vaginally delivered infants, a doubling of alpha diversity was associated
with a 62% increase in in having an additional respiratory infection or symptom of
respiratory infection (RR = 1.62, 95% CI: 1.23-2.15) (Figure 3.1, Supplementary Table
3.3). A doubling of alpha diversity was associated with a doubling of the risk of
wheezing for which a medication was prescribed (RR = 2.00, 95% CI: 1.16-3.45) and an
86% increase in diarrhea requiring a doctor visit (RR = 1.86, 95% CI: 1.14-3.03) among
vaginally delivered infants (Figure 3.1, Supplementary Table 3.3). We did not observe
consistent associations among cesarean-delivered infants.
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Figure 3. 1: Dot and Whisker Plots of Adjusted Relative Risk Estimates and 95%
Confidence Intervals from GEE Analysis of Infant 6-Week-old Stool 16S V4-V5 rRNA
Sequencing Alpha Diversity and Infections and Symptoms of Infection over the First
Year of Life

Abbreviations: GEE, generalized estimating equation; N, sample size; RR, relative risk; RTI,
respiratory tract infection. Overall GEE adjusted for maternal BMI, delivery type, sex, breast feeding
at six weeks, perinatal antibiotic use, and gestational age. GEE stratified by delivery mode (vaginal
and cesarean) adjusted for maternal BMI, sex, breast feeding at six weeks, perinatal antibiotic use, and
gestational age. Points represent relative risk, and vertical lines above and below points represent
upper and lower confidence bands. Relative risk estimates represent an increased risk of having an
additional infection or symptom of infection or an increased risk of experiencing wheezing or diarrhea
with each doubling of the inverse Simpson index. Upper RTI, lower RTI, and wheezing outcomes are
those diagnosed by a physician for which a medication was prescribed. Diarrhea outcomes are those
diagnosed by a physician for whom no medication was prescribed. Numbers above upper confidence
bands indicate the total number of outcomes, which may be greater than N due to repeated measures.
Sample sizes were N = 464 for overall and N = 125 for cesarean delivery for diarrhea analyses due to
missing data.

3.4.3 Metagenomics: Species-Level
In the GEE of metagenomics species data, the doubling of the relative abundance of
Veillonella unclassified was positively associated with having an additional respiratory
infection or symptom of respiratory infection in the first year of life (RR = 1.02; 95% CI:
1.01-1.04) (Figure 3.2.1). In examining specific outcomes, we found that diarrhea was
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positively associated with the relative abundance of Streptococcus peroris and negatively
associated with the relative abundance of Streptococcus salivarius (Figure 3.3).

Stratified by delivery mode, we found that having an additional respiratory
infection or symptom of respiratory infection was positively associated with
Haemophilus influenzae among cesarean-delivered infants (RR = 1.02; 95% CI: 1.011.04) (Figure 3.2.3). Veillonella parvula, Corynebacterium pseudodiphtheriticum, and
Corynebacterium pseudodiphtheriticum were positively associated, while Clostridium
butyricum and Coprobacillus unclassified were negatively associated, with a risk of an
additional upper RTI among infants delivered by cesarean section (Figure 3.3).
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Figure 3. 2: Volcano Plots of GEE Adjusted Relative Risk Estimates of the Number of
Infections and Symptoms over the First Year of Life in Relation to 6-Week
Metagenomics Species Relative Abundance
1. Overall (N = 185)

2. Vaginal Delivery (N = 129)
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3. Cesarean Delivery (N = 56)

Abbreviations: GEE, generalized estimating equation; N, sample size; RR, relative risk.
Estimates shown for taxa prevalent in over 10% of subjects. The gray line represents a log10transformed FDR threshold of 0.1. Blue points indicate statistically significant taxa at α = 0.05. Red
points indicate taxa selected by FDR correction. The size of the points is scaled by relative abundance.
Relative risk estimates represent an increased risk of having an additional infections or symptoms of
infection with each doubling of relative abundance. a. Volcano plot of unstratified GEE adjusted for
maternal BMI, delivery type, sex, breast feeding at six weeks, perinatal antibiotic use, and gestational
age. b. Volcano plot of vaginal deliveries adjusted for maternal BMI, sex, breast feeding at six weeks,
perinatal antibiotic use, and gestational age. c. Volcano plot of cesarean deliveries adjusted for
maternal BMI, sex, breast feeding at six weeks, perinatal antibiotic use, and gestational age. Three
taxa were removed due to high RRs and low p-values.
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Figure 3. 3: Forest Plot of Metagenomics Species Associated with the Number of
Infections and Symptoms of Infections in the First Year of Life

Abbreviations: N, sample size; RTI, respiratory tract infection; RR, relative risk.
Species selected by FDR correction presented in the forest plot. Species for vaginal deliveries did not
meet the FDR threshold of 0.1. Squares represent RR, and horizontal lines represent 95% confidence
intervals. Green represents a positive association, and purple represents a negative association.
Relative risk estimates represent an increased risk of having an additional upper respiratory infection
or an increased risk of experiencing diarrhea with each doubling of the relative abundance.

3.5 Discussion
In our prospective study of infants from the general population in New Hampshire, USA,
we observed patterns of the early microbiome that were related to the occurrence of
infant respiratory infections, wheezing, and diarrhea. Higher diversity of the early infant
gut microbiome was associated with a greater number of respiratory infections and
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symptoms over the first year of life. Relationships between early microbial patterns and
infant outcomes differed by delivery mode, a known contributor to the developing
microbiome13, with stronger associations with alpha diversity among infants born by
cesarean section. Using metagenomic sequencing, we found that Veillonella in any
delivery mode and Haemophilus in cesarean deliveries were among the species
associated with an increased risk of infant respiratory infections and symptoms.

Our analyses found associations with many bacterial species that are commonly found in
oral flora, though these bacteria have also been detected in the gut. An early driver of the
gut microbiome is diet. One prospective study found that exclusive breastfeeding was
inversely related to lower respiratory tract infections among infants and asthma and
allergic rhinitis among children four years of age166. The same study highlighted the
potential mediating effect of the gut microbiome on the relationship between exclusive
breastfeeding and outcomes. Additionally, infants born operatively may be relatively
more likely to acquire the genera of such species through breast milk160.

Respiratory Infections
In our study, Veillonella, specifically Veillonella parvula, was positively associated with
upper respiratory infections, especially in cesarean-delivered infants. Veillonella parvula
is commonly found in oral flora, although it is observed in both oral and gut
ecosystems167. We are not aware of studies that have examined Veillonella parvula.
However, consistent with our findings, a prospective study of 120 Dutch infants found an
abundance of three Veillonella operational taxonomic units using 16S V4 rRNA
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sequencing among one-week-old infants that was associated with a higher number of
respiratory infections in the first year of life47. In mechanistic studies, Veillonella parvula
produces propionate in the human gut, which may stimulate IL10-producing Treg
differentiation168,169, and in the small intestine, it induces IL-8, IL-1β, IL-10, and TNFα170.

Among cesarean-delivered infants in our study, a higher relative abundance of
Corynebacterium species was associated with a greater risk of upper RTIs.
Corynebacterium species are generally characterized as pathobionts in the respiratory
tract171. Case series have suggested that Corynebacterium pseudodiphtheriticum in the
sputum is a driver of pulmonary infection172,173, and a case-control study of the
nasopharyngeal microbiome from France found enriched Corynebacterium
pseudodiphtheriticum in subjects with viral respiratory tract infections compared to
healthy controls (N = 178)174.

Upper respiratory tract infections in our cohort were associated with a decreased
abundance of Clostridium butyricum in infant stool samples. One Clostridium butyricum
strain upregulated inhibitory cytokines such as IL-10 in a mouse model175. Clostridium
species can promote Treg production and inhibit inflammatory cytokines32,176, with some
associated with systemic infections in humans177. Thus, the potential inhibitory impact of
Clostridium butyricum on an infant’s immune response to infection requires further
investigation.
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Cesarean-delivered infants in our study had a positive association between
Haemophilus influenzae and the number of any respiratory infections and symptoms.
Haemophilus influenzae is a bacterial species known to cause several types of infectious
diseases, including those of the respiratory tract. Although previous studies have not
found associations between Haemophilus influenza in the gut microbiome and respiratory
infections, the species do reside in the intestinal tract178. Further explorations of the gutlung axis, as well as the origin of such bacteria in the gut, are warranted179.

Other studies have also found associations between the gut microbiome and
respiratory infections. Observations from epidemiologic studies that were not found in
our study included a higher abundance of Bifidobacterium and Enterococcus and a lower
abundance of Escherichia-Shigella, Prevotella, Faecalibacterium and Enterobacter in
subjects aged 0 to 3 years with pneumonia compared to healthy controls (N = 33) in a
cross-sectional study of Mongolian children46. A case-control study of US infants found
that infants with a higher gut alpha diversity of Bacteroides had a higher likelihood of
developing bronchiolitis (N = 155)48. Findings from the aforementioned Dutch
prospective study found several associations between the bacterial taxa of the infant gut
microbiome and the number of respiratory infections, including associations with
Bifidobacterium, Bacteroides, and Enterococcus (N = 120). These findings, as well as
ours, require further confirmation.

We found a positive prospective association between the overall alpha diversity at
six weeks of life and the risk of upper RTIs. Although our findings for alpha diversity
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may seem contradictory to some prior studies that reported negative associations between
alpha diversity and health outcomes180, our study focuses on the early microbiome when
diversity is low in healthy babies. We further prospectively examined associations with
respiratory infections. Similar to our study, other studies found no associations between
alpha diversity and adverse health outcomes but observed differences in the abundance of
specific microbes158. A cross-sectional study from the US found that infants hospitalized
for severe RSV infection had slightly lower alpha diversity of the gut than infants with
moderate RSV infection and controls (N = 95)159. However, as the infants’ gut
microbiomes were assessed after the onset of disease, reverse causality was possible in
this study; thus, further prospective studies are needed to understand how the overall
microbial diversity and colonization of the neonatal and early infant gut reflect immune
response to infections.

Wheezing
Wheezing is a respiratory symptom associated with infection, atopy, allergy or a later
diagnosis of asthma. We found an association between a higher alpha diversity and an
increased risk of wheezing identified by a physician, and this was largely among
vaginally delivered infants. Epidemiologic studies have reported associations between the
infant gut microbiome and atopic wheezing and asthma in childhood181–184. Whether our
findings translate to a later risk of asthma will require longer-term follow-up of our
cohort.
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Diarrhea
Among infants in our study, higher alpha diversity was associated with an increased risk
of diarrhea requiring a physician visit in the first year of life. Other prospective studies
are lacking, and to our knowledge, prior work includes only case-control studies that
measured the infants’ stool microbiomes at the time of symptoms. For example, in a
small case-control study from South Africa, lower alpha diversity was observed in the
stool of infants with gastrointestinal disease compared to infants with respiratory disease
and infants with other diseases (N = 34)185. In addition to the issue of reverse causality,
diarrheal diseases in the US vary in etiology and consequences compared to those in
other geographic regions.

We observed that an increased relative abundance of Streptococcus peroris and a
reduced relative abundance of Streptococcus salivarius were associated with a higher risk
of diarrhea seen by a physician. Limited data also exist on microbiome composition in
relation to diarrheal disease, again with most studies being cross-sectional and with
relatively small sample sizes. A study from China of 20 infants with diarrheal illness and
13 controls found differences in gut microbiome composition, with two patients having a
higher abundance of Streptococcus peroris than controls186. Other studies designed to
detect pathogens among ill infants and young children compared to controls using 16S
rRNA sequencing have also noted a higher abundance of Streptococcus species
associated with diarrheal illness187,188. In mice, Streptococcus salivarius strains inhibited
inflammation with severe and moderate colitis189. In the same experiment, Streptococcus
salivarius inhibited the activation of the NF-κB pathway, which induces
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proinflammatory gene expression in intestinal epithelial cells189. Together, these findings
raise the possibility of a role of Streptococcus species in susceptibility to diarrhea in early
childhood.

Our study had a number of strengths as well as limitations. We carefully collected
infant stool samples at approximately six weeks of age from a cohort of pregnant women
and their offspring from the general population, and we examined repeated measurements
of infection occurrences, respiratory symptoms, and diarrhea and a broad range of
potential confounding variables, such as maternal prepregnancy BMI, delivery mode,
infant sex, breast feeding at six weeks, antibiotic use during pregnancy, and gestational
age, for the analyses. A major challenge to the analysis of microbiome sequencing data is
the ability to fully capture their correlated, compositional, and high-dimensional nature
when assessing longitudinal outcomes. Therefore, we performed our analyses on the
relative abundance of individual species and corrected for multiple hypotheses using the
false discovery rate (FDR). Our outcomes were not ascertained by viral or bacterial
culture or PCR to confirm the type of infection; as a result, we relied on responses of
telephone surveys from caregivers. Additionally, we could not differentiate between the
various causes of wheezing and diarrhea in our dataset. Participant recall is a potential
source of bias; however, efforts were made to reduce misclassification by including
questions on the duration and severity of illness and limiting our analyses to outcomes
that involved either a physician visit or a prescription medication. In a review of infants’
pediatric medical records, we found caregiver responses to be at least 80% concordant
with physician assessments documented in the medical record (unpublished data).
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Furthermore, while our study is one of the largest overall, we had limited statistical
power in our analyses stratified by delivery mode.

In conclusion, our findings from a prospective birth cohort of US infants suggest
that the composition of the microbiome in early life influences the most common health
outcomes of infancy, which in turn may have consequences for lifelong disease risk.
While higher alpha diversity was associated with respiratory infections and symptoms
overall and among vaginal deliveries, the doubling of the relative abundance of
unclassified Veillonella species and Haemophilus influenza species increased the risk of
an additional respiratory infection or symptom overall and among cesarean-born infants
respectively. Our findings may help to inform interventions aimed at altering the
microbiome during this critical window of immune training27.
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4.1 Abstract
The establishment of the gut microbiome plays a key symbiotic role in the developing
immune system; however, its influence on vaccine response is yet uncertain. We
prospectively investigated the composition and diversity of the early-life gut microbiome
in relation to infant antibody response to two routinely administered vaccines. Eightythree infants enrolled in the New Hampshire Birth Cohort Study were included in the
analysis. We collected blood samples at 12 months of age and assayed the isolated serum
to quantify total IgG and measured antibody to pneumococcal capsular polysaccharide
and tetanus toxoid. Stool samples were collected from infants at six weeks of age and
sequenced using 16S rRNA, and a subset of 61 samples were sequenced using shotgun
metagenomics sequencing. We observed differences in beta diversity for 16S six-week
stool microbiome and pneumococcal and tetanus IgG antibody responses. Metagenomics
analyses identified species and metabolic pathways in six-week stool associated with
tetanus antibody response, in particular, negative associations with the relative abundance
of Aeriscardovia aeriphila species and positive associations with the relative abundance
of species associated with CDP-diacylglycerol biosynthesis pathways. The early gut
microbiome composition may influence an infant’s vaccine response.

4.2 Introduction
Vaccines reduce infant mortality and morbidity from infections worldwide190. The World
Health Organization and the US American Association of Pediatrics guidelines outline a
standard schedule of immunizations for infants to provide protection against potentially
fatal infectious diseases. Rates of vaccine administration vary globally191. Among
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children born in the US in 2016 and 2017, approximately 99% of infants received
vaccines, with only 1.2% not receiving any vaccines by 24 months of age192. However,
immune responses to vaccinations vary by host with reported factors being
sociodemographic characteristics, perinatal exposures, breast or formula feeding,
antibiotic use, and variation in timing and other characteristics of the vaccination itself193.

The early establishment of infant gut microbiome is now known to play an essential role
in the development of the immune system25,26. Growing evidence points to the impact of
the gut microbiome on immune response to vaccination, including among infants treated
with antibiotics 59,194–197. For example, recent studies examined the relation between
infant gut microbiota and response to oral poliovirus, bacille Calmette-Guérin, tetanus
toxoid, hepatitis B virus, and rotavirus vaccines among infants living in Bangladesh,
Ghana, and Pakistan49–51. These studies identified specific bacterial taxa in the intestinal
microbiome associated with differential vaccine response and microbial compositions in
high vaccine responders to be similar to those of healthy infants from high income
countries50,51. Prospective studies are lacking in common vaccine response in relationship
to the very earliest development of the intestinal microbiome. To gain a better
understanding of the role of the infant gut microbiome on vaccine response, we
investigated the association between the early infant gut microbiome composition and
antibody response to two common vaccines administered in the first year of life -pneumococcal capsid protein and tetanus toxoid -- at one year of age in the New
Hampshire Birth Cohort Study (NHBCS).
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4.3 Methods
4.3.1 Study Population
The current study included participants in the NHBCS who had stool samples collected at
approximately 6 weeks of age for microbiome analyses and infant blood samples at
approximately 12 months of age for vaccine response assays. The NHBCS comprised of
pregnant women aged 18-45 with a singleton pregnancy who received care at prenatal
clinics in New Hampshire, USA as described previously123. We collected longitudinal
survey data for maternal and infant lifestyles, and we ascertained infant birth
characteristics and vaccine information from delivery and pediatric medical records. The
Committee for the Protection of Human Subjects at Dartmouth College approved all
protocols, and informed consent was obtained from all participants upon enrollment.

4.3.2 Blood sample collection, serum isolation, and assaying
Infant blood samples were collected from well child visits scheduled at approximately
12-months of age post-partum. Serum was isolated from the blood samples, frozen at 80oC, and shipped to Stanford University in Palo Alto, California for serological analysis.
Antibody responses to pneumococcus capsule-based vaccines were measured using
VaccZyme Anti-PCP IgG Enzyme Immunoassay kit (Binding Site, Birmingham, UK).
Antibody responses to tetanus toxoid-based vaccines were measured using Tetanus
Toxoid IgG ELISA (Genway Biotech, San Diego, CA).
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4.3.3 Stool sample collection, DNA extraction, sequencing, and profiling
Infant stools samples were collected at approximately 6 weeks of age as described
previously124,160. These samples were aliquoted and frozen at -80oC, and DNA was
extracted from thawed samples using Zymo DNA extraction kit (Zymo Research, Irvine,
CA). OD260/280 nanodrop was used to measure sample quality and purity. Samples were
sent to Marine Biological Laboratory in Woods Hole, Massachusetts for bacterial 16S
rRNA gene sequencing of the V4-V5 hypervariable region using Illumina MiSeq
(Illumina, San Diego, CA). We conducted quality control measures internally by
amplifying in triplicate with one negative control as described previously160. We inferred
amplicon sequence variants (ASVs) using DADA2161 and assigned taxonomies using the
SILVA database162. A subset of stool samples also underwent shotgun metagenomics
sequencing using Illumina NextSeq (Illumina, San Diego, CA) as previously
described156. DNA samples were extracted and sheared to a mean insert size of 400 bp
using a Covaris S220 focused ultrasonicator, and sequencing libraries were constructed
with Nugen’s Ovation Ultralow V2 protocol. We merged and trimmed DNA reads using
KneadData163, inferred taxonomic profiles at the species-level using Metaphlan3198, and
profiled metabolic pathways using HUMAnN3.0198.

4.3.4 Statistical Analysis
We examined the association between the stool microbiome and antibody response to
pneumococcal capsular polysaccharide (PCP) and tetanus toxoid (TT). Using the 16S
data, we aggregated ASVs to genera and calculated beta diversity using Bray-Curtis
dissimilarity. We used PERMANOVA to test the differences between groups. Using the
metagenomics data, we log2-transformed the relative abundance of bacterial species and
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metabolic pathways. We removed species that were present in less than 10% of subjects
and performed linear regression on all remaining taxa. We further investigated metabolic
pathways by removing pathways that were present in less than 10% of subjects and
standardizing the relative abundance of pathways. We used elastic-net to select pathways
with possible associations with vaccine response. We then conducted linear regression on
each elastic-net selected pathway with FDR correction.

We applied a False Discovery Rate (FDR) threshold of 0.1 to adjust for multiple testing.
Factors associated with both the gut microbiome and vaccine response were considered
potential confounders and included in all analyses, including infant birth weight (g),
breast feeding at 6 weeks (exclusively breast fed/ever formula fed), and maternal prepregnancy BMI (kg/m2). Since delivery mode is not associated with vaccine response, it
was not considered a potential confounder. For missing confounding data, we assumed
entries were missing at random and used multiple imputation by chained equations and
the predictive mean matching method to impute missing data in a randomly chosen
iteration. All analyses were performed in R version 3.4.3, using functions diversity,
vegdist, ade4, adonis, mice, and cv.glmnet in packages ‘vegan’, ‘mice’, and ‘glmnet’.

We also performed a sensitivity analysis of 65 infants in whom we verified that they had
received at least one dose of Pneumococcal Conjugate Vaccine (PCV) 13 or Diphtheria,
Tetanus, and acellular Pertussis vaccine (DTaP) in their pediatric medical records.
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4.4 Results
4.4.1 Baseline Characteristics
We measured vaccine response in 155 study infants for PCP and 133 subjects for TT. Of
those with PCP vaccine response data, 80 stool samples were analyzed by 16S and 59 by
metagenomics sequencing. For TT response, 68 infants had 16S data and 53 had
metagenomics sequencing data. Our study group had a roughly equal distribution of male
(54.2%) and female (45.8%) infants (Table 4.1). Nearly 80% of subjects were delivered
vaginally, and roughly half (53.4%) had been exclusively breast fed at 6 weeks of life
(Table 4.1). Mean infant birth weight was 3342g and mean maternal pre-pregnancy BMI
was 26.1 (Table 4.1). The mean PCP antibody response was 30.4mg/L (SD = 22.5), and
the mean tetanus toxoid antibody response was 0.932 IU/mL (SD = 0.759). The 80
infants in our study who had both pneumococcal vaccine response measurements and 16S
sequence data all had pneumococcal vaccine response measurements above the preferred
PCP protection threshold of 0.2 mg/L199. Of the 68 infants who had tetanus vaccine
response measurements and 16S data, 6 subjects (8.8%) had measurements below the
preferred TT protection threshold of 0.1 IU/mL (Supplementary Figure 4.1)200.
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Table 4. 1: Selected Baseline Characteristics of Infants and Mothers in the New
Hampshire Birth Cohort Study (N = 83)
Variable
Infant Characteristics
Sex, No. (%)
Female
Male
Delivery Mode, No. (%)
Vaginal
Caesarian
Breast Feeding at 6 Weeks, No. (%)
Exclusively breast fed
Fed any formula
Breast Feeding at 1 Year, No. (%)
Exclusively breast fed
Fed any formula
Daycare (ever in first year of life), No. (%)
Yes
No
Birthweight (g), mean (SD)
Received PCV13 vaccine, No. (%)
At least one dose recorded in medical record
None
Received DTaP vaccine, No. (%)
At least one dose recorded in medical record
None
PCP Vaccine Response (mg/L), mean (SD)
TT Vaccine Response (IU/mL), mean (SD)
Maternal Characteristics
Maternal pre-pregnancy BMI (kg/m2), mean
(SD)
Parity, No. (%)
0
1+

Sample Size

No. (%) or Mean
(SD)

83
38 (45.8%)
48 (54.2%)
83
65 (78.3)
18 (21.7)
73
39 (53.4)
34 (46.6)
73
19 (26.0)
54 (74.0)
63

82
66

35 (55.6)
28 (44.4)
3342g (558)
65 (98.5)
1 (1.5)

66
80
68

65 (98.5)
1 (1.5)
30.4 (22.5)
0.932 (0.759)

83

26.1 (5.7)

83
44 (53.0)
39 (47.0)
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4.4.2 16S V4-V5 rRNA Gene: Beta Diversity
In PERMANOVA analyses of pair-wise community composition, we observed a weak
association between PCP antibody response at or below versus above the median
(PERMANOVA P = 0.112) (Figure 4.1.1). We further observed a borderline statistically
significant difference in beta diversity for TT antibody response at or below the TT
protection threshold and above the threshold (PERMANOVA P = 0.065) (Figure 4.1.2).

Figure 4. 1: PCoA plots of bacterial 16S V4-V5 rRNA sequencing Bray-Curtis
Dissimilarity for PCP and TT. PCP groups assigned by median PCP IgG concentration
threshold. TT groups assigned by preferred protection threshold of 0.1IU/mL.
Percentages on the X and Y axis of plots represent percentage of variance explained by
first two eigenvectors.

4.4.3 Metagenomics: Species and Pathways
Streptococcus oralis species was inversely associated with PCP antibody response
although the association did not meet FDR threshold (Figure 4.2.1). Aeriscardovia
aeriphila was inversely associated with TT antibody response, whereas Staphylococcus
aureus, Escherichia coli, Streptococcus thermophilus, and Anaerococcus vaginalis were
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positively associated with TT antibody response (Figure 4.2.2). Of these, only
Aeriscardovia aeriphila remained statistically significant after FDR correction (Figure
4.2.2) (Supplementary Table 4.1).
Figure 4. 2: Associations between metagenomics bacterial species and vaccine response.
Dots indicate bacterial species, and size of dots vary by mean abundance. Blue indicates
species with p-value < 0.05. Red indicates species with p-values <0.05 and meet FDR
correction.
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Several metabolic pathways were found to be associated with vaccine response. The 9
pathways associated with lower PCP vaccine response included higher abundance of taxa
related to aerobic respiration I (cytochrome c), superpathway of L-phenylalanine
biosynthesis, superpathway of pyrimidine deoxyribonucleotides de novo biosynthesis,
myo-, chiro-, and scillo-inositol degradation, and ketogenesis (Fig. 4.3.1) (Supplementary
Table 4.2). In contrast, higher abundance of taxa related to pantothenate and coenzyme A
biosynthesis III, superpathway of pyrimidine ribonucleosides degradation,
methylphosphonate degradation II, and superpathway of pyrimidine ribonucleotides de
novo biosynthesis were associated with higher PCP antibody response (Fig. 4.3.1)
(Supplementary Table 4.2). Five pathways were positively associated with TT antibody
response, including CDP-diacylglycerol biosynthesis I, purine nucleotides degradation II
(aerobic), queuosine biosynthesis, CDP-diacylglycerol biosynthesis II, and adenosine
nucleotides degradation II (Fig. 4.3.2) (Supplementary Table 4.2). No inverse
associations were observed for TT.

Figure 4. 3: Associations between elastic-net and metabolic pathways and vaccine
response. Dots indicates effect size, and horizontal bands indicate 95% CI. Green dots
represent positive association, while purple dots represent negative association. Size of
dots vary by p-value: larger dot indicates smaller p-value. Only pathways selected by
elastic net and FDR correction shown here.
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Our sensitivity analyses of infants with medical record confirmation of vaccination
revealed similar results. Results are provided in Supplementary Figure 4.2,
Supplementary Figure 4.3, and Supplementary Figure 4.4 for beta diversity, bacterial
species, and metabolic pathways respectively.
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4.5 Discussion
In a prospective study of the infant gut microbiome using both 16S and metagenomic
sequencing, we observed differences in infant gut microbiome composition at six weeks
of age in relation to pneumococcal conjugate and tetanus toxoid vaccines at one year of
age. Microbial community structure (beta diversity) was associated with both PCP and
TT antibody response although with limited statistical power. In analyses of individual
bacterial species, associations were observed with decreased antibody response to TT
including Aeriscardovia aeriphila after correction for multiple comparisons. Pathway
analyses indicated several potential mechanisms by which microbial metabolites might
influence vaccine response especially those related to CDP-diacylglycerol biosynthesis.

Guidelines by the AAP in the US state that children under 2 years of age should receive
three doses of PCV13 that provide protection against 13 strains of Streptococcus
pneumoniae201. These microbes are responsible for the majority of invasive bacterial
infections in infants and young children, including otitis media infections, resulting in
significant morbidity, antibiotic exposure, and at times difficulty with hearing202.
Streptococcus also results in pneumonia, “pink eye”, and other infectious illnesses in
children 2 months and older, hindering daycare attendance, and with consequent financial
loss to working parents. Following PCV, antibodies to PCP antigens conjugated to a
carrier protein are induced by both T cell and B cell responses203. Tetanus is a lifethreatening infection that is caused by Clostridium tetani and is preventable by a toxoid
vaccine. It is part of several combination vaccines including DTaP201. DTaP primarily
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induces T cell response204. By age one, most infants in the US would have received three
doses of PCV13 and DTaP201.

Using 16S V4-5 rRNA sequencing data, we found marginally statistically significant
between-group (beta diversity) differences in PCP and TT antibody response. One prior
study of Chinese infants observed differences in beta diversity among those with and
without a positive oral poliovirus IgA vaccine response based on 16S rRNA analyses of
stool collected the day of vaccination. However, many prior studies have not detected
such differences with either oral poliovirus205 or rotavirus vaccination206,207.

The association between specific microbial taxa and infant vaccine response has been
examined in only a few prospective studies of infants. In a study of 48 Bangladeshi
infants, positive associations were found for Corynebacterium and Bifidobacterium and
negative associations for Escherichia/Shigella and Acinetobacter and T cell proliferation
response to tetanus toxoid vaccine among young infants (measured at 15 weeks of life)49.
In this study, a positive association for Actinomyces and a negative association for
Staphylococcus with IgG response to TT vaccine also were observed. Further, a positive
association was identified between Bifidobacteriaceae and tetanus toxoid T cell
proliferation response. This contrasts with our finding of an inverse association with
Aeriscardovia aeriphila, a bacterial species of the family Bifidobacteriaceae. A later
publication from the Bangladesh cohort of infants found a positive association between
Bifidobacterium and CD4 and IgG response to vaccines, including to the TT vaccine at
age 2 years52. Other studies have focused on vaccine response to oral live attenuated
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rotavirus. For instance, a case-control study of 78 Ghanaian infants found negative
correlations between rotavirus vaccine response in serum collected four weeks after the
last vaccine dose and Bacteroides and Prevotella species, and positive correlations with
bacteria in the Bacilli phylum in 6 week stool samples collected before vaccination50.
Similarly, in a study performed in Pakistan, a case-control study found positive
correlation between rotavirus vaccine response 28 days after the last vaccine dose and
relative abundance of Clostridium cluster XI and Proteobacteria, including Serratia and
Escherichia coli in the pre-vaccination stool of 20 infants51. A randomized control trial
found correlations between Bifidobacteria and antipoliovirus IgA response in 30 French
infants208. Another study of polio vaccine in 107 Chinese infants found increased
Firmicutes and decreased Actinobacteria in stool collected the day of the last oral
poliovirus vaccine dose among infants with negative IgA response205. Many of these
studies investigated response to oral vaccines, and gut microbiota may interact differently
with oral vaccines compared to intramuscular vaccines due to direct contact between oral
vaccines and the gut. Thus, further studies are needed in diverse study populations and
with response to multiple types of vaccines.

External factors that influence both the gut microbiome and vaccine response highlight
opportunities for recommendations and interventions to improve vaccine response. Germfree mice treated with antibiotics and mice deficient in toll-like receptor 5 expression
have demonstrated lower responses to influenza vaccine, but not other vaccines197.
Diminished vaccine response was restored after reconstituting their gut microbiome with
flagellated E. coli. In another mouse experiment, lower antibody response after
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ovalbumin and Freund's adjuvant immunization was observed in infant mice whose
mothers were treated with antibiotics during pregnancy196. The study also observed that
germ-free mice with deficient antibody response can increase their response after
introduction to normal gut flora, raising the possibility that interventions may be able to
enhance immune response. A similar study in mice found associations between maternal
and early-life antibiotic exposure and gut microbiome dysbiosis and lower IgG responses
for several vaccines, including PCV13 and Hexa, which produces antibodies to tetanus59.
Further, impaired PCV13 response in mice treated with antibiotics was not observed if
they received fecal transplant from age-matched untreated mice, while impaired response
remained in mice treated with antibiotics and fecal transplant from antibiotic treated
mice. Further experimental studies and mediation analyses will help establish the
potential for microbiome-directed interventions to bolster immune response to vaccines.

Further evidence of the importance of the microbiome on vaccine response comes from
studies on beneficial effects of probiotics. A study of 20 French infants found those given
Bifidobacterium breve strain C50 and Streptococcus thermophilus supplementation in the
first 4 months of life had higher antipoliovirus IgA response at 4 months208. Interestingly,
in our analyses, we observed a positive association between Streptococcus thermophilus
and TT antibody response, although this was no longer statistically significant after FDR
correction. Prenatal and early life supplementation with Lactobacillus rhamnosus GG, L.
rhamnosus LC705, Bifidobacterium breve Bbi99, and Propionibacterium freudenreichii
ssp. shermanii in the first 6 months of life was associated with higher IgG antibody
response to Haemophilus influenzae type b at 6 months of age in a randomized controlled
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study of 61 allergy-prone Finnish infants209. A randomized control study of 61 mothers
and their infants found maternal Lactobacillus rhamnosus GG supplementation starting at
36 weeks gestation was associated with lower IgG response of tetanus toxoid,
Haemophilus influenzae type b, and several serotypes of PCV7 vaccines in infants at 12
months of age210. Thus, further research on antibiotic use and prenatal and early life
probiotic supplementation is warranted to elucidate immunomodulation by gut
microbiota.

Based on metagenomic analysis, we found several metabolic pathways associated with
PCP and TT vaccine response. Nucleotides including purine and pyrimidine have an
important role in the immune system. Several pathways involving pyrimidine were
associated with differential response to PCP. A link between pyrimidine biosynthesis and
the immune system has been observed211,212. Furthermore, the purine nucleotide
degradation II pathway was observed to be positively associated with TT response in our
study. CDP-diacylglycerol biosynthesis I and II were positively associated with TT
response in our study. CDP-diacylglycerol has an important function in lipid metabolism,
which could affect the immune system213.

The main strength of our study is the prospective analyses of early-life infant gut
microbiome and vaccine response. However, there also were limitations. Due to the high
dimensional nature of microbiome data and available sample size, our analyses had
limited statistical power. Therefore, we applied a filtering process as well as
regularization techniques for dimension reduction and variable selection. Delivery mode
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was not related to vaccine response, and therefore, not included as a covariate in our
analyses. Several potential confounders, such as breast feeding, were adjusted for in our
analyses; however, residual confounding remains a possibility. Further work is warranted
to investigate the gut microbiome as a possible mediator or effect modifier on the
relationships between exposures and vaccine response. Delivery mode and breast feeding
are two such exposures associated with relative abundance of gut bacteria214, and
associations with these exposures have been observed in our cohort124,215. Breast feeding
may influence a child’s vaccine response193. Analyses with larger sample sizes may be
able to identify mediating or modifying effects as well as to corroborate or refute
associations lacking statistical significance after correction for multiple hypotheses found
in our species and pathway analyses.

In conclusion, we found patterns of the developing gut microbiome captured at a very
early time point in development associated with differential response to vaccines
administered in the first year of life. The microbes and pathways associated with antibody
response to PCP and TT may offer clues to the critical role the developing microbiome
plays in shaping the immune system as measured by vaccine response. Our findings
provide insight into possible interventions to optimize antibody response and improve
vaccine efficacy during a critical time in early immune maturation and when
susceptibility to infection is at its highest.
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5.1 Abstract

The human microbiome has an important role in determining health. Mediation analyses
quantify the contribution of the microbiome in the causal path between exposure and
disease; however, current mediation models cannot fully capture the high dimensional,
correlated, and compositional nature of microbiome data and do not typically
accommodate dichotomous outcomes. We propose a novel approach that uses inverse
odds weighting to test for the mediating effect of the microbiome. We use simulation to
demonstrate that our approach gains power for high dimensional mediators, and it is
agnostic to the effect of interactions between the exposure and mediators. Our application
to infant gut microbiome data from the New Hampshire Birth Cohort Study revealed a
mediating effect of 6-week infant gut microbiome on the relationship between maternal
prenatal antibiotic use during pregnancy and incidence of childhood allergy by 5 years of
age.

5.2 Introduction

The human gut microbiome and immune system interact to form a bidirectional
relationship 26, and the developing gut microbiome plays a crucial role in immune system
maturation in infancy 25. As a result, perturbations in the gut microbiome is linked to
clinical outcomes through infancy and childhood, and into adulthood. External factors
shape the gut microbiome including delivery mode, diet, and antibiotic use 53.
Understanding the three-way interplay among external factors, the gut microbiome, and
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clinical outcomes can help generate opportunities for intervention such as therapeutics
and probiotics for modulating the gut microbiome to improve health outcomes.

Mediation analysis quantifies the contribution of a variable in the causal pathway
between an exposure or treatment and an outcome. These analyses are especially useful
in health research to determine possible interventions to prevent disease or produce better
health outcomes. Upon development of approaches to mediation analysis including
traditional approaches 63,64 and causal inference approaches 65–68,216, many extensions of
mediation analyses have also been published in recent years. These include models for
multiple mediators 68,69 and those that account for interactions between exposures and
mediators 217,218. Other approaches include inverse odds ratio weighting (IORW) 219 or
inverse odds weighting (IOW) 220 to quantify the total, direct, and indirect effects. Testing
the mediation effect can be conducted using common approaches such as the Sobel test
221

and the joint significance test 64.

Mediation analysis for high dimensional mediators has become increasingly popular for
modeling biomarkers. These include methods using PCA and regularization for
dimension reduction 70–73, multiple testing procedures 74–79, and others 80,81. Methods for
mediation analysis have also extended to microbiome data: many test for mediation with
continuous outcome 82–87, some account for interactions between exposure and mediators
84,87

, and one conducts mediation analysis for dichotomous outcomes 88. Most of these

methods, however, require specification of the microbiome model, which is difficult due
to the sparse, high dimensional, and compositional nature of microbiome data.
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Furthermore, to our knowledge, none of them can accommodate both dichotomous
outcomes and high dimensional microbiome mediators.

We propose a novel approach, HT-MMIOW, a Hypothesis Test approach for
Microbiome Mediation using IOW, that tests the mediation effect of high dimensional
microbiome data on both continuous and dichotomous outcomes using IOW. This
approach uses the isometric log-ratio transformation (ilr) to account for the compositional
nature of microbiome data and reduces dimensions using the Uniform Manifold
Approximation and Projection (UMAP). The components generated form UMAP serve
as mediator variables. A permutation test is performed to determine the statistical
significance of the overall microbial mediation effect. Our simulation results demonstrate
that this new approach is well powered when the number of true mediators is large or the
indirect effect is large. We present an application of our approach to infant gut
microbiome data to detect a mediating effect between antibiotic exposure and a diagnosis
of allergy before the age of 5.

5.3 Methods
5.3.1 Identification
Suppose the exposure, mediator, and outcome are denoted by an # × 1 vector (, an
# × ! matrix ), and an # × 1 vector * respectively. * is known to succeed ), and ) is
known to succeed (. The microbiome matrix ) is composed of abundance of ! taxa for
each subject in #, and there are + true mediators in ). For simplicity, let both ( and * be
dichotomous. Let , be an # × - matrix of covariates. Under the Baron and Kenny’s
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classical mediation framework for a single mediator ., mediation analysis is represented
by the following equations:

/012+(Pr * = 1 6)) = 89 + 8; (
([.|6] = ?9 + ?; (
/012+(Pr * = 1 6, A)) = B9 + B; ( + BC .

The direct effect of ( on * is B; , the indirect effect of ( on * through . is ?; BC , and the
total effect is 8; = B; + ?; BC . The Sobel test determines the existence of an indirect
effect with the hypothesis D9 : ?; BC = 0 vs DG : ?; BC ≠ 0.

5.3.2 Dimension reduction of microbiome data
The standard mediation model requires the knowledge of true mediators. Mediation
models for multiple mediators exist, but many assume that mediators are independent or
that the causal relationship between mediators are known. However, microbiome data is
high dimensional, compositional, and correlated. We do not know which microbial taxa
are true mediators, and we do not know the causal relationships among taxa. We propose
mapping the microbiome data from the Aitchison-simplex to Euclidean space and
reducing the dimensions to obtain a smaller set of mediation features.
The ilr is an extension of log-ratio transformations for compositional data that extends on
traditional additive (alr) and centered (clr) log-ratio transformations. Briefly, alr is the
log-ratio of a value in the composition and a reference value, and clr is the log-ratio of a
value and the geometric mean of values in the composition. There are, however,
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limitations to these approaches; alr produces transformations do not preserve distances,
and clr produces transformations with a singular covariance matrix. In Ilr, distance is
preserved when data is transformed from the !-dimensional Aitchison space to the ! − 1
dimensional Euclidean space, and the resulting vectors are orthogonal and interpretable in
analyses 222. Each value of ilr transformation is a !balance" between two subsets of ),
denoted by J for those on the left of the balance and K for those on the right of the
balance:
2/L J, K =

LM
1(AQ )
log
L+M
1(AR )

where L is the cardinality of J, M is the cardinality of K, AQ are the values in J, AR are
the values in K, and 1 ∙ is the geometric mean function.
We impute a pseudocount of 0.5 to zero values and apply ilr to the microbiome data to
account for compositionality. After ilr, we reduce dimensionality using UMAP. Briefly,
UMAP is a fast dimension reduction procedure that models the manifold with a fuzzy
topological structure by searching for a low-dimensional projection with the closest
possible equivalent fuzzy topological structure 223. UMAP allows for non-linear
dimension reduction and meaningful separation between clusters. Applying UMAP on
2/L ) transforms our microbiome data to an # × B matrix T, where B is a user-specified
number of components.
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5.3.3 Compute the indirect effect and perform permutation test for mediation
The IORW and IOW approach for causal mediation analysis allows for the
decomposition of the total effect to direct effect and indirect effect. This approach can
accommodate multiple mediators due to a weighting procedure that removes the need to
specify the model to regress the multiple mediators on exposure. This approach is
advantageous for microbiome data because of the difficulty in modeling the joint
conditional density of high dimensional, compositional, and correlated microbiome
features. Using the IOW approach, the total effect of exposure ( on outcome *, given
covariates U, can be estimated using the model:

ℎ * (, U = V9 + (V; + UVC

(1)

where V; represents the total effect of ( on *, given U. ℎ(∙) is the user-specified link
function and W represents the error. We implement IOW to condense the association
between ( and mediators T, conditional on U. The weights can be estimated using the
model with a user-specified link function X(∙):
X ( T, U = Y9 + TY; + UYC

(2)

For each observation, the weight is the inverse of the predicted odds in the exposed group
and 1 for the unexposed group. Using IOW as opposed to IORW stabilizes the weights,
though it may introduce small bias to estimates 220. We then use a weighted regression
model to estimate the direct effect of ( on *, conditional on U.

ℎ `* `(, `U = a9 ` + `(a; + `UaC

(3)
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where a; represents the direct effect of ( on *, given U, and ` is an # × 1 vector of
weights. Due to this weighting procedure, we do not need to specify interactions between
( and T.

We can now estimate the indirect effect using parameters from (1) and (3), which
becomes our observed test statistic for our permutation test: bcde = V; − a; . The null
hypothesis of no mediation effect of the microbiome is expressed by:
D9 ∶ V; − a; = 0,
and the alternative hypothesis that a mediation effect of the microbiome exists is
expressed by:
DG ∶ V; − a; ≠ 0.
Our permutation test can calculate the P-value using the formula

j
kl; g(

b (h) >

bcde )/n, where B is the total number of permutations, g ∙ is an indicator function,
b (k) is the test statistic under the null hypothesis for permutation X = 1, … , n.

5.4 Simulation
3.1 Simulation overview

We conducted simulations to evaluate the power of our proposed approach on continuous
and dichotomous outcomes. We simulated ( and ) using SparseDOSSA 224. Briefly, this
tool uses zero-inflated log-normal distribution to simulate realistic microbial community
structure of human stool and covariates that correlate with the simulated microbiome
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data. We applied UMAP on ) to reduce dimensionality to 2 components. We set the
effect size of the exposure on outcome at 5, the percentage of microbial features
associated with the exposure at 50%, and effect size of the exposure on mediator at 3 for
simulated data generation using SparseDOSSA. We simulated outcomes * using a
standard logistic regression with the exposure and scaled relative abundance of true
microbial taxa. mediators selected at random from those associated with the exposure,
with the effect size of the exposure on outcome set at 5 and a random noise of of p 0,1 .
Exposure variables were dichotomous, and outcome variables were continuous and
dichotomous.

To fine-tune our approach, we evaluated the performance of HT-MMIOW with various
dimension reduction techniques. These include 1) UMAP as described previously; 2)
PCA to n-components then UMAP; 3) PCA with components explaining 100% of the
variance; and 4) PCA with components explaining 80% of the variance. We investigated
varying effect sizes of true mediators on outcome (effect size = 0.5, 1, 5), which serve as
proxy for smaller to larger indirect effects, and varying number of true mediators in the
microbiome sample (+ = 1, 5, 10). We also varied sample sizes (# = 50, 70, 100, 150,
300, 500) and the number of taxa in the microbiome data (! = n, 2n). We compared the
performance of HT-MMIOW with a distance-based omnibus test using Bray-Curtis and
Jaccard distances 83. Though the omnibus test is designed for continuous outcomes, we
sought to examine its performance on dichotomous outcomes due to the lack of methods
for high dimensional microbiome mediators and dichotomous outcomes. All analyses
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were conducted using R version 4.0.2 and packages “SparseDOSSA2”, “magrittr”,
“dplyr”, “ggplot2”, “compositions”, “umap”, “foreach”, “doParallel”, and “bda”.

3.2 Simulation results

Figures 5.1 and 5.2 display the simulation results of HT-MMIOW for continuous
outcomes under varying conditions compared with the omnibus test. HT-MMIOW with
UMAP dimension reduction performs better than HT-MMIOW with PCA and UMAP
when the number of taxa are twice the of sample size. HT-MMIOW also performs better
than the omnibus test for all conditions, especially when the number of true mediators is
small. Using HT-MMIOW with only PCA as the dimension reduction technique did not
perform well. HT-MMIOW with PCA components explaining 80% of the variance
generally performed better than HT-MMIOW with PCA components explaining 100% of
the variance, and this may be because fewer components in the inverse odds ratio
mediation approach provides more power. These power calculations were based on an
empirical threshold of 0.05. Though type I error for continuous outcomes were around
0.05 based on the 0.05 empirical threshold, type I error based on an empirical threshold
of 0.01 were smaller (Supplementary Figure 5.1). HT-MMIOW using a 0.01 empirical
threshold continued to yield higher power than the omnibus distance test (Supplementary
Figure 5.2) .
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Figure 5. 1: Power calculations for varying sample size, effect size, and number of true
mediators for continuous outcomes and ! = #. Results are based on 200 simulations.
Each line represents the hypothesis test procedures evaluated.
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Figure 5. 2: Power calculations for varying sample size, effect size, and number of true
mediators for continuous outcomes and ! = 2#. Results are based on 200 simulations.
Each line represents the hypothesis test procedures evaluated.

For dichotomous outcomes, HT-MMIOW performed well with stronger effect of
mediators on Y and with larger numbers of true mediators in M (Figure 5.3, Figure 5.4).
Using UMAP performed just as well as using PCA and UMAP. HT-MMIOW also
performed better than the omnibus test in all conditions. Again, HT-MMIOW’s
performance was lower when using only PCA as the dimension reduction technique. As
expected, performances for both continuous and dichotomous outcomes increased with
increasing sample size. Again, the above power calculations were based on an empirical
threshold of 0.05. The type I error for dichotomous outcomes were inflated when an
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empirical threshold of 0.05 was used; however, type I error based on an empirical
threshold of 0.01 were close to zero (Supplementary Figure 5.1). HT-MMIOW using a
0.01 empirical threshold for dichotomous outcomes yielded higher power than the
omnibus distance test (Supplementary Figure 5.3).

Figure 5. 3: Power calculations for varying sample size, effect size, and number of true
mediators for dichotomous outcomes and ! = #. Results are based on 200 simulations.
Each line represents the hypothesis test procedures evaluated.
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Figure 5. 4: Power calculations for varying sample size, effect size, and number of true
mediators for dichotomous outcomes and ! = 2#. Results are based on 200 simulations.
Each line represents the hypothesis test procedures evaluated.

5.5 Application to NHBCS data
Prenatal antibiotic use has been linked to development of infant and childhood allergy
16,156

, and it is also associated with compositional differences in the infant gut

microbiome 225. We applied HT-MMIOW to test the effect of the infant gut microbiome
as a potential mediator in the causal path between prenatal antibiotic use and allergy on
data from the New Hampshire Birth Cohort Study (NHBCS). The NHBCS is a
prospective birth cohort of mother-infant dyads who received prenatal care in New
Hampshire clinics. The study recruited pregnant women with ages ranging between 18
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and 45, who had a singleton pregnancy and were served by a private water system as
described previously 123. Prenatal use of antibiotics was reported in prenatal records. The
child’s caregivers reported whether the child had any allergies diagnosed by a physician
during telephone interviews conducted when infants turned approximately 4, 8, 12, and
18 months of age, and then at 1 year intervals thereafter. Infant stools samples were
collected at approximately 6 weeks of age and sequenced using Illumina MiSeq
(Illumina, San Diego, CA) for bacterial 16S rRNA gene sequencing of the V4-V5
hypervariable region at Marine Biological Laboratory in Woods Hole, Massachusetts. We
inferred amplicon sequence variants using DADA2 161 and assigned taxonomies using the
SILVA database 162.

A total of 412 mother-infant dyads were included in this analysis. Of these, 72 mothers
(17.5%) self-reported to antibiotic use during pregnancy, and 39 children (9.5%) had
been diagnosed with allergy by 5 years of age. Based on the 16S sequencing reads of our
stool samples, we identified 705 different genera of bacteria. In our mediation test, HTMMIOW produced a P-value of 0.02; this gives us evidence to reject the null hypothesis
and suggest that the infant gut microbiome mediates the relationship between antibiotic
use during pregnancy and incidence of allergy. Due to variable duration of follow-up, we
adjusted for age at which allergy was first diagnosed or age at last follow-up in our
model.
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5.6 Discussion
We proposed a novel hypothesis test for microbiome mediation effect that utilizes a
dimension reduction procedure for microbiome data and a mediation analysis procedure
utilizing IOW to test if an indirect effect exists. Our simulation scenarios evaluated the
power of our approach under varying conditions. HT-MMIOW was highly powered when
the effect of the mediator on the microbiome was large or when the number of true
mediators in the microbiome data was large. Compared to a conventional hypothesis test,
HT-MMIOW generally performed better for both continuous and dichotomous outcomes.
Our approach is one of the only hypothesis tests that can test for the indirect effect in
high dimensional microbiome mediators and dichotomous outcomes.

Our proposed hypothesis test is flexible in its application. HT-MMIOW can be used for
multiple types of exposure and outcome data; the user may specify their own link
functions in the regression models. Our approach can also be adjusted to account for
other types of high dimensional mediation analysis, including genomics, by replacing the
centered log-ratio transformation step to a transformation of the user’s choice. The total
effect, direct effect, and indirect effect can be calculated using the IOW approach, and
confidence intervals can be estimated using bootstrap methods.

The main strength of our approach is that HT-MMIOW reduces high-dimensional
microbiome data to a few independent components that are representative of microbial
community structure. The IOW procedure accommodates multiple mediators in the
mediation model. Furthermore, the IOW frameworks eliminates the need to specify a
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model to regress the exposure on the joint conditional density of multiple compositional
mediators. Another strength is that IOW does not require us to specify the interaction
between exposure and mediators, even if they exist.
Despite its strengths, HT-MMIOW is not without limitations. One limitation of our
approach is that the mediation effect of true microbial mediators must be large for the
approach to detect an indirect effect. We must also assume that there is no unmeasured
confounding. Additionally, the number of true mediators must be large for smaller
mediation effects and smaller samples sizes. Our method also cannot detect the mediation
effect of specific microbes or clusters of microbes. Nevertheless, this approach serves as
an important first step in determining whether a mediation effect exists. Further work is
warranted to identify key microbial features and interactions responsible for driving this
effect.
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Chapter 6: Concluding Remarks
There is increasing recognition of the important role exposures and the early gut
microbiome play in the health of infants and young children. In this thesis, I investigated
the three-way interplay among exposures, the infant gut microbiome, and outcomes in
infants enrolled in the NHBCS. Our longitudinal analysis of 572 infants found that each
month earlier of introduction to rice cereal, which contains inorganic arsenic, was
associated with increased risk of upper RTI, lower RTI, acute respiratory symptoms, and
allergy. We also found positive associations between 16S alpha diversity of 6-week gut
microbiome and respiratory infections in infancy. Microbial species profiled from
metagenomics sequencing also were found to be associated with respiratory infections in
infancy. Our analysis of six-week gut microbiome and vaccine response detected several
bacterial species and metabolic pathways associated with PCP and TT antibody response.
Lastly, we introduced HT-MMIOW, a hypothesis test procedure that detects microbiome
mediation using UMAP to reduce the number of dimensions in the mediator and IOW to
quantify the overall indirect effect. HT-MMIOW detected a statistically significant
indirect effect of the six-week gut microbiome on the “causal” path between maternal
antibiotic use during pregnancy and incidence of child allergy up to five years of age.

This thesis found associations between exposures, the early gut microbiome, and
outcomes in infancy and early childhood; however, we cannot conclude causal
relationships. We attempted to rule out associations that may be driven by other
covariates with confounder adjustment in our analyses. In our mediation models assumed
that unmeasured confounding did not have a large contribution to our risk ratios as this
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assumption is required for performing mediation analysis with observational data. Further
research is warranted to identify the mechanisms that explain the causal link among
exposures, gut microbiota, and outcomes.

Infant infections are still a leading cause of morbidity and mortality in the US and other
countries. Further, the widespread prevalence of allergy is of great public health concern.
In addition to the health-related burden for the individual, allergies can pose a significant
economic burden in terms of healthcare costs and loss of caregiver income.
Understanding the three-way interplay among exposures, the gut microbiome, and infant
and child outcomes may aid the development of novel interventions or therapies aimed at
modulating the gut microbiome to reduce the rates of infant morbidity and mortality with
lifelong health impacts, such as infections and allergies.
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Appendices
Supplementary Figure 2. 1: Flow Diagram of Study Participants with Inclusion and
Exclusion Criteria
1760 NHBCS pregnancies
enrolled as of October 2017

1760 Infants with at least
one complete follow-up
survey
808 Excluded due to
incomplete follow up to age
of 8 months

983 Infants with follow-up
data from 8 to 18 months

572 Infants included in GEE
analysis

54 excluded due to
restriction to those with rice
cereal consumption
information, and 357
excluded due to additional
restriction to those with
incomplete outcome data at
the next follow-up interval

Abbreviations: NHBCS, New Hampshire Birth Cohort Study; GEE, generalized estimating equation.
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Supplementary Table 2. 1: Selected Characteristics of Mothers and Infants (N = 411) in
the New Hampshire Birth Cohort Study Not Included in Main Analyses Followed to Age
18 Months
Variable
Maternal Characteristics
Smoking during any trimester of pregnancy,
No. (%)
Yes
No
Relationship status, No. (%)
Married
Single
Separated/Divorced
Highest level of educational attainment, No.
(%)
≤high school/GED
Some college
College graduate
Postgraduate schooling
BMI before pregnancy (kg/m2), mean (SD)
Age at enrollment (years), mean (SD)
Arsenic in water (µg/L), mean (SD)
Water Arsenic > 5 µg/L, No. (%)
Infant Characteristics
Sex, No. (%)
Male
Female
Birth weight (g), mean (SD)
Ever breast fed at 4 months, No. (%)
Yes
No
Other solid food consumption at 4 months,
No. (%) c
Yes
No
Other solid food consumption at 8 months,
No. (%) c
Yes
No
Other solid food consumption at 12 months,
No. (%) c
Yes
No

Sample Size

Mean (SD) or No.
(%)

372
55 (14.8%)
317 (85.2 %)
366
293 (80.1)
56 (15.3)
17 (4.6)
367

398
411
390
390

49 (13.4)a
70 (19.1)a
135 (36.8) a
113 (30.8)a
26 (6.0)
31.1 (4.9)
4.2 (13.5)
66 (16.9)

410
398
350

188 (45.9)
222 (54.1)
3447 (496)
333 (95.1)
17 (4.9)

88
78 (88.6)
10 (11.4)
47
26 (55.3)
21 (44.7)
315
53 (16.8)
262 (83.2)
83

a

Percentages do not sum to 100 due to rounding

Supplementary Table 2. 2: Infant Rice Cereal Consumption and Immune-Related
Outcome Prevalence
Variable

N

Ever consumed rice cereal before age of 12 months
Yes
No
Age of rice cereal introduction of those consumed
before age of 12 months (months)
Rice cereal introduced before 4 months of age
Rice cereal introduced between 4-8 months of age
Rice cereal introduced between 8-12 months of
age
Rice cereal consumption at 4 monthsa
Yes
No
Time since rice cereal introduction at 4 months
(months)
Rice cereal consumption at 8 monthsa
Yes
No
Time since rice cereal introduction at 8 months
(months)
Rice cereal consumption at 12 monthsa
Yes
No
Time since rice cereal introduction at 12 months
(months)
Infections or symptoms within 5-18 months of life
At least one outcome
At least one outcome lasting ≥ 2 days
At least one outcome resulting in a doctor visit
At least one outcome treated with prescription
medication
Allergy within 5-18 months of life
At least one outcome
At least one outcome resulting in a doctor visit
Reported an allergy to peanuts

572
435

Mean (SD)
or N (%)
435 (76.0)
137 (24.0)
5.2 (1.3)
27 (6.2)
381 (87.6)
27 (6.2)

358
435

42 (11.7)
316 (88.3)
0.02 (0.1)

438
572

305 (69.6)
133 (30.4)
1.4 (1.3)

544

572

373 (68.6)
171 (31.4)
4.4 (2.7)

572
552 (96.5)
523 (91.4)
373 (65.2)
299 (52.3)
572
77 (13.5)
45 (7.9)
5 (0.9)
84

Reported an allergy to other nuts
Reported an allergy to eggs
Reported an allergy to other foods
Reported an allergy to antibiotics
Reported an allergy to cats or dogs
Reported an allergy to pollen
Reported an allergy to latex
Reported an allergy to dust
Reported an allergy to insect bites
Reported an allergy to grass

3 (0.5)
7 (1.2)
39 (6.8)
21 (3.7)
4 (0.7)
9 (1.6)
2 (0.3)
2 (0.3)
2 (0.3)
5 (0.9)

Abbreviations: SD, standard deviation.
a

Percentage calculated using different sample sizes due to missing values. Sample sizes were 358,

438, and 544 for 4 months, 8 months, and 12 months respectively.

85

Supplementary Table 2. 3: Number of Immune-related Outcomes over 5-18 Months at Each Time Period, N = 572
Outcome

Upper Respiratory
Infections
Lower Respiratory
Infections
Acute Respiratory
Symptoms
Diarrhea

Fever Symptoms a

Allergy

a
b

Time Period

8 months
12 months
18 months
8 months
12 months
18 months
8 months
12 months
18 months
8 months
12 months
18 months
8 months
12 months
18 months
8 months
12 months
18 months

Any report
of the
outcome
No.(%)
206 (74.9)
340 (83.1)
399 (90.9)
17 (6.2)
28 (6.8)
33 (7.5)
133 (48.4)
202 (49.4)
251 (57.2)
46 (16.7)
124 (30.3)
159 (36.2)
101 (36.7)
210 (51.3)
252 (57.8)
11 (4.0)
27 (6.6)
53 (12.1)

Lasting ≥ 2
days
No.(%)

Involving a
doctor visit
No.(%)

177 (64.4)
292 (71.4)
341 (77.7)
17 (6.2)
27 (6.6)
28 (6.4)
99 (36.0)
143 (35.0)
189 (43.1)
15 (5.5)
40 (9.8)
57 (13.0)
32 (11.6)
84 (20.5)
95 (21.6)

103 (37.5)
155 (37.9)
171 (38.9)
16 (5.8)
26 (6.4)
31 (7.1)
53 (19.3)
70 (17.1)
81 (18.5)
11 (4.0)
16 (3.9)
18 (4.1)
36 (13.1)
70 (17.1)
85 (19.4)
6 (2.2)
17 (4.2)
37 (8.4)

N/Ab

Requiring a
prescription
medication
No.(%)
58 (21.1)
119 (29.1)
146 (33.3)
9 (3.3)
18 (4.4)
24 (5.5)
18 (6.5)
31 (7.6)
44 (10.0)
0 (0.1)
2 (0.5)
1 (0.2)
4 (1.5)
12 (2.9)
23 (5.2)
N/Ab

Sample size N = 571 for fever analyses
Participants only asked about any allergies and whether these allergies had been doctor diagnosed
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Supplementary Table 2. 4: Adjusted Risk Ratio Estimates and 95% Confidence Intervals From GEE in Repeated Measures over 5-18
Months for One Month Earlier Introduction of Rice Cereal on Risk of Immune-related Outcomes, N = 572a.
Outcome

Any report of the outcome
Lasting ≥ 2 days
Involving a doctor visit
Requiring a prescription medication
RR (95% CI)
RR (95% CI)
RR (95% CI)
RR (95% CI)
N of total events
N of total events
N of total events
N of total events
Upper Respiratory
1.03
1.03
1.02
1.04
Infections
(1.02-1.04)
(1.01-1.05)
(0.98-1.06)
(1.00-1.09)
945
810
429
323
Lower Respiratory
1.14
1.10
1.13
1.19
Infections
(1.01-1.29)
(0.97-1.24)
(1.00-1.29)
(1.02-1.39)
78
72
73
51
Acute Respiratory
1.05
1.05
1.03
1.10
Symptoms
(1.02-1.08)
(1.01-1.10)
(0.96-1.10)
(1.00-1.22)
586
431
204
93
c
Diarrhea
1.08
1.05
0.89
(1.04-1.13)
(0.96-1.15)
(0.74-1.06)
329
112
45
3
b
Fever Symptoms
1.04
1.03
1.07
1.22
(1.01-1.07)
(0.97-1.09)
(1.00-1.14)
(1.02-1.45)
563
211
191
39
d
d
Allergy
1.18
N/A
1.20
N/A
(1.07-1.30)
(1.06-1.36)
91
60
Abbreviations: RR, risk ratio; CI, confidence interval.
a
GEE adjusted for smoking during pregnancy, maternal relationship status, maternal education, maternal pre-pregnancy BMI, maternal age of
enrollment, arsenic concentrations in household tap water samples, infant birth weight, breastfeeding, and other solid food consumption. Risk ratios
represent increased risk of health outcome with every month earlier of introduction to rice cereal.
b
Sample size N = 571 for fever analyses
c
Too few observations to perform analysis
d
Participants only asked about any allergies and whether these allergies had been doctor diagnosed
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Supplementary Table 2. 5: Crude Risk Ratio Estimates and 95% Confidence Intervals From GEE for all Other Covariates on Risk of
Immune-related Outcomes, N = 572a.
Variable
Intercept
Indicator of Rice Cereal Consumption
Other Solid Food Consumption
Smoking during any trimester of pregnancy
Relationship status – Married (baseline) VS Single
Relationship status – Married (baseline) VS
Separated/Divorced
Highest level of educational attainment – ≤high
school/GED (baseline) VS Some college
Highest level of educational attainment – ≤high
school/GED (baseline) VS College graduate
Highest level of educational attainment – ≤high
school/GED (baseline) VS Postgraduate schooling
BMI before pregnancy
Age at enrollment
Birth weight
Ever breast fed at 4 months
Arsenic in water
a

Upper Respiratory
Infections
0.21
(0.06, 0.66)

Lower Respiratory
Infections
0.00
(0.00, 0.07)

Acute Respiratory
Symptoms
0.02
(0.00, 0.20)

Diarrhea

Fever Symptoms

0.14
(0.00, 5.82)

0.01
(0.00, 0.26)

5.98
(0.17, 212.93)

1.32
(0.98, 1.78)

0.70
(0.27, 1.83)

0.77
(0.41, 1.43)

2.35
(0.82, 6.72)

0.94
(0.24, 3.62)

1.42
(0.53, 3.84)

1.19
(0.89, 1.63)
1.26
(0.91, 1.74)
1.01
(0.65, 1.58)
1.28
(0.76, 2.16)
0.78
(0.50, 1.22)
1.03
(0.70, 1.52)
0.89
(0.58, 1.36)
1.00
(0.99, 1.02)
1.00
(0.98, 1.02)
1.00
(1.00, 1.00)
1.25
(0.75, 2.08)
0.99
(0.97, 1.01)

1.07
(0.44, 2.57)
0.80
(0.29, 2.18)
0.95
(0.32, 2.80)
0.86
(0.11, 6.58)
0.82
(0.28, 2.39)
0.64
(0.24, 1.66)
0.89
(0.34, 2.36)
1.06
(1.02, 1.10)
1.04
(0.98, 1.10)
1.00
(1.00, 1.00)
1.53
(0.39, 5.95)
1.01
(0.98, 1.04)

1.43
(0.83, 2.48)
1.35
(0.67, 2.71)
2.09
(1.01, 4.32)
2.26
(0.83, 6.18)
1.04
(0.46, 2.32)
1.04
(0.46, 2.38)
1.48
(0.62, 3.52)
1.02
(0.99, 1.06)
1.02
(0.97, 1.06)
1.00
(1.00, 1.00)
1.71
(0.50, 5.87)
1.01
(0.98, 1.04)

2.22
()0.86, 5.78
1.36
(0.63, 2.94)
1.91
(0.70, 5.19)
1.41
(0.27, 7.39)
0.98
(0.35, 2.73)
0.71
(0.24, 2.09)
0.86
(0.23, 3.22)
0.98
(0.92, 1.05)
0.97
(0.90, 1.05)
1.00
(1.00, 1.00)
0.73
(0.15, 3.49)
1.00
(0.97, 1.06)

2.04
(0.66, 6.29)
0.89
(0.35, 2.30)
0.73
(0.19, 2.91)
3.05
(0.87, 10.71)
1.95
(0.43, 8.90)
1.47
(0.33, 6.55)
1.31
(0.27, 6.32)
0.99
(0.95, 1.04)
1.05
(0.98, 1.11)
1.00
(1.00, 1.00)
0.58
(0.20, 1.65)
0.88
(0.77, 1.01)

2.68
(1.02, 7.05)
0.56
(0.20, 1.59)
0.89
(0.30, 2.63)
1.90
(0.20, 17.77)
0.51
(0.18, 1.43)
0.45
(0.17, 1.23)
0.74
(0.26, 2.13)
0.92
(0.87, 0.98)
0.95
(0.89, 1.01)
1.00
(1.00, 1.00)
0.28
(0.11, 0.74)
1.00
(0.97, 1.03)

b

Allergy

Outcomes include those treated with prescription medication for upper RTI, lower RTI, acute respiratory symptoms, and fever symptoms and those
diagnosed by a doctor for diarrhea and allergy.
b
Sample size N = 571 for fever analyses
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Supplementary Table 2. 6: Crude Risk Ratio Estimates and 95% Confidence Intervals From GEE in Repeated Measures over 5-18
Months for One Month Earlier Introduction of Rice Cereal on Risk of Immune-related Outcomes, N = 572a.
Outcome

Any report of the
outcome
RR (95% CI)
N of total events
1.03
(1.01-1.04)
945
1.14
(1.01-1.28)
78

Lasting ≥ 2 days
RR (95% CI)
N of total events

Involving a doctor visit
RR (95% CI)
N of total events

Requiring a prescription medication
RR (95% CI)
N of total events

1.03
(1.01-1.04)
810
1.10
(0.97-1.24)
72

1.02
(0.98-1.05)
429
1.14
(1.00-1.29)
73

1.04
(0.99-1.08)
323
1.18
(1.01-1.38)
51

Acute Respiratory
Symptoms

1.05
(1.02-1.08)
586

1.05
(1.01-1.09)
431

1.03
(0.96-1.09)
204

1.11
(1.01-1.23)
93

Diarrhea

1.08
(1.03-1.13)
329
1.03
(1.00-1.06)
563
1.17
(1.07-1.29)
91

1.06
(0.97-1.15)
112
1.02
(0.96-1.08)
211
d
N/A

0.89
(0.75-1.07)
45
1.06
(0.99-1.13)
191
1.19
(1.07-1.33)
60

c

Upper Respiratory
Infections
Lower Respiratory
Infections

Fever Symptoms

Allergy

b

3
1.25
(1.03-1.51)
39
d
N/A

Abbreviations: RR, risk ratio; CI, confidence interval.
a
Crude GEE. Risk ratios represent increased risk of health outcome with every month earlier of introduction to rice cereal.
b
Sample size N = 571 for fever analyses
c
Too few observations to perform analysis
d
Participants only asked about any allergies and whether these allergies had been doctor diagnosed
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Supplementary Table 2. 7: Associations between Rice Cereal Introduction Age in Months
and Confounders, N = 572a
Confounder
Smoking during any trimester of pregnancy
Yes
No (reference)
Relationship status
Married (reference)
Single
Separated/Divorced
Highest level of educational attainment
≤high school/GED (reference)
Some college
College graduate
Postgraduate schooling
BMI before pregnancy (kg/m2)
Age at enrollment (years)
Birth weight (g)
Ever breast fed at 4 months
Yes
No (reference)
a

Estimate

Standard Error

P-Value

0.1970

0.1970

0.0194

-0.7455
-1.3096

0.2224
0.4715

0.0009
0.0057

0.2373
0.4876
0.7134
-0.0255
0.03234
-0.0001

0.2563
0.2317
0.2367
0.0111
0.0132
0.0001

0.3550
0.0359
0.0027
0.0223
0.0150
0.2810

1.1638

0.3009

0.0001

Associations calculated using univariate linear models.
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Supplementary Figure 3. 1: Composition of 6-week Gut Microbiome of Infants in the
NHBCS
A. Heat map of 20 most common genera from 16S sequencing data (N = 465)
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B. Heat map of 20 most common species from metagenomics sequencing data (N = 185)
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Supplementary Table 3. 1: Number of Immune-related Outcomes over 12 Months at Each
Time Period for 16S Analysesa
Outcome
Any Infections or
Symptoms
Upper Respiratory
Infections
Lower Respiratory
Infections
Wheezing

Diarrhea

Time Period
4 months
8 months
12 months
4 months
8 months
12 months
4 months
8 months
12 months
4 months
8 months
12 months
4 months
8 months
12 months

Overall
N = 465
55
189
244
30
109
156
5
26
18
4
19
20
7
11
18

Vaginal Delivery
N = 339
37
133
200
21
79
126
4
18
16
2
14
16
5
9
13

Cesarean Delivery
N = 126
18
56
44
9
30
30
1
8
2
2
5
4
2
2
5

a

For any infections or symptoms, 18 entries were imputed. For upper RTI, 3 entries were imputed. For
lower RTI, 3 entries were imputed.
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Supplementary Table 3. 2: Number of Immune-related Outcomes over 12 Months at
Each Time Period for Metagenomics Analysesa
Outcome
Any
Infections or
Symptoms
Upper
Respiratory
Infections

4 months
8 months
12 months
4 months
8 months
12 months

Overall
N = 185
16
72
119
12
48
72

Lower
Respiratory
Infections

4 months
8 months
12 months

0
6
8

0
3
7

0
3
1

Wheezing

4 months
8 months
12 months
4 months
8 months
12 months

1
6
11
3
4
7

0
3
8
2
3
5

1
3
3
1
1
2

Diarrhea

a

Time Period

Vaginal Delivery
N = 129
11
42
96
10
31
58

Cesarean Delivery
N = 26
5
30
23
2
17
14

For any infections or symptoms, 7 entries were imputed.
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Supplementary Table 3. 3: Adjusted Relative Risk Estimates and 95% Confidence Intervals from GEE Analysis of Infant 6-Week
Stool 16S V4-V5 rRNA Sequencing Alpha Diversity and Infections and Symptoms of Infection over the First Year of Life a

Outcome
Any Infection or
Symptomc
Upper RTI
Lower RTI
Wheezing
Diarrhead

Overall
N = 465
RR

95% CI

488

1.39*

(1.1, 1.77)

370

1.62*

(1.23, 2.15)

118

0.95

(0.58, 1.55)

295
49
43
36

1.40*
1.50
1.30
1.44

(1.12, 1.76)
(0.87, 2.6)
(0.81, 2.07)
(0.92, 2.25)

226
38
32
27

1.85
1.89
2.00*
1.86*

(0.98, 3.51)
(0.96, 3.72)
(1.16, 3.45)
(1.14, 3.03)

69
11
11
9

0.94
0.94
0.47
0.74

(0.27, 3.29)
(0.28, 3.21)
(0.20, 1.12)
(0.32, 1.69)

No. of
Outcomesb

Vaginal Delivery
N = 339
No. of
RR
95% CI
b
Outcomes

Cesarean Delivery
N = 126
No. of
RR
95% CI
b
Outcomes

Abbreviations: GEE, generalized estimating equation; N, sample size; No., number; RR, relative risk; CI, confidence interval; RTI, respiratory tract
infection.
*indicates statistical significance at ! = 0.05.
a
Overall GEE adjusted for maternal BMI, delivery type, sex, breast feeding at six weeks, perinatal antibiotic use, and gestational age. GEE stratified by
delivery mode (vaginal and cesarean) adjusted for maternal BMI, sex, breast feeding at six weeks, perinatal antibiotic use, and gestational age. Relative
risk estimates represent an increased risk of having an additional infection or symptom of infection or an increased risk of experiencing wheezing or
diarrhea with each doubling of the inverse Simpson index. Upper RTI, lower RTI, and wheezing outcomes are those diagnosed by a physician for which a
medication was prescribed. Diarrhea outcomes are those diagnosed by a physician for which no medication was prescribed.
b
Total number of outcomes may be greater than N due to repeated measures.
c
Any infection or symptom is the sum of upper respiratory tract infections (RTI), lower RTI, and acute respiratory symptoms.
d
Sample sizes N = 464 for overall and N = 125 for cesarean delivery for diarrhea analyses due to missing data.
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Supplementary Figure 4. 1: PCP and TT IgG antibody concentrations.
a. PCP

b. TT

Violin plots of PCP and TT IgG concentration indicating concentration quartiles. Red dotted line
indicates preferred protection threshold of 0.2mg/L for PCP and 0.1IU/mL for TT.
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Supplementary Table 4. 1: Bacterial species associated with vaccine response after correction for multiple comparisons
Outcome Species
TT
Aeriscardovia aeriphila

Estimate
-0.037

P-value
< 0.001

95% CI
(-0.057, -0.017)

Estimate
-0.271
0.263
-0.238
0.305
-0.275

P-value
0.045
0.046
0.057
0.021
0.034

95% CI
(-0.530, -0.013)
(0.010, 0.515)
(-0.478, 0.002)
(0.053, 0.556)
(-0.522, -0.027)

-0.239
0.334
0.323
-0.234
0.882
0.707
0.784
0.881
0.706

0.058
0.007
0.011
0.063
< 0.001
< 0.001
< 0.001
< 0.001
0.002

(-0.482, 0.003)
(0.100, 0.567)
(0.084, 0.562)
(-0.476, 0.008)
(0.468, 1.295)
(0.284, 1.13)
(0.368, 1.199)
(0.468, 1.294)
(0.282, 1.129)

Supplementary Table 4. 2: FDR selected metabolic pathways associated with vaccine response
Outcome
PCP
PCP
PCP
PCP
PCP
PCP
PCP
PCP
PCP
TT
TT
TT
TT
TT

Pathway
PWY-3781: aerobic respiration I (cytochrome c)
PWY-4242: pantothenate and coenzyme A biosynthesis III
PWY-6628: superpathway of L-phenylalanine biosynthesis
PWY-7209: superpathway of pyrimidine ribonucleosides degradation
PWY-7211: superpathway of pyrimidine deoxyribonucleotides de novo
biosynthesis
PWY-7237: myo-, chiro- and scillo-inositol degradation
PWY-7399: methylphosphonate degradation II
PWY0-162: superpathway of pyrimidine ribonucleotides de novo biosynthesis
PWY66-367: ketogenesis
PWY-5667: CDP-diacylglycerol biosynthesis I
PWY-6353: purine nucleotides degradation II (aerobic)
PWY-6700: queuosine biosynthesis
PWY0-1319: CDP-diacylglycerol biosynthesis II
SALVADEHYPOX-PWY: adenosine nucleotides degradation II
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Supplementary Figure 4. 2: Sensitivity analysis PCoA plots of bacterial 16S V4-V5
rRNA sequencing Bray-Curtis dissimilarity for PCP and TT
a. PCP (PERMANOVA P = 0.688)

b. TT (PERMANOVA P = 0.112)

PCP groups assigned by median PCP IgG concentration threshold. TT groups assigned by preferred
protection threshold of 0.1IU/mL. Percentages on the X and Y axis of plots represent percentage of
variance explained by first two eigenvectors.
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Supplementary Figure 4. 3: Sensitivity analysis associations between metagenomics
bacterial species and vaccine response.
a. PCP

b. TT

Dots indicate bacterial species, and size of dots vary by mean abundance. Blue indicates species with
p-value < 0.05. Red indicates species with p-values <0.05 and meet FDR correction.
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Supplementary Figure 4. 4: Sensitivity analysis associations between elastic-net and
metabolic pathways and TT response.

No associations were found for PCP response. Dots indicates effect size, and horizontal bands indicate
95% CI. Green dots represent positive association, while purple dots represent negative association.
Size of dots vary by p-value: larger dot indicates smaller p-value. Only pathways selected by elastic
net and FDR correction shown here.
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Supplementary Figure 5. 1: Type I error calculations for varying sample size, number of
taxa, and type of outcome.

Results are based on 1000 simulations. Each line represents type I error at varying empirical
thresholds.
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Supplementary Figure 5. 2: Power calculations for HT-MMIOW with a 0.01 threshold
and the omnibus distance test for continuous outcomes, with varying sample size, effect
size, and number of true mediators and number of taxa.

Results are based on 200 simulations. Solid lines indicate ! = 2$, and dashed lines indicate ! = $.
Green lines represent HT-MMIOW with a 0.01 empirical threshold, and blue lines represent the
omnibus distance test.
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Supplementary Figure 5. 3: Power calculations for HT-MMIOW with a 0.01 threshold
and the omnibus distance test for dichotomous outcomes, with varying sample size, effect
size, and number of true mediators and number of taxa.

Results are based on 200 simulations. Solid lines indicate ! = 2$, and dashed lines indicate ! = $.
Green lines represent HT-MMIOW with a 0.01 empirical threshold, and blue lines represent the
omnibus distance test.

103

References
1. Gupta, R. et al. The Economic Impact of Childhood Food Allergy in the United States.
JAMA Pediatrics 167, 1026–1031 (2013).
2. Amand, C., Tong, S., Kieffer, A. & Kyaw, M. H. Healthcare resource use and economic
burden attributable to respiratory syncytial virus in the United States: a claims
database analysis. BMC Health Services Research 18, 294 (2018).
3. Ladomenou, F., Moschandreas, J., Kafatos, A., Tselentis, Y. & Galanakis, E. Protective
effect of exclusive breastfeeding against infections during infancy: a prospective
study. Archives of Disease in Childhood 95, 1004–1008 (2010).
4. Duijts, L., Jaddoe, V. W. V., Hofman, A. & Moll, H. A. Prolonged and Exclusive
Breastfeeding Reduces the Risk of Infectious Diseases in Infancy. Pediatrics 126,
e18–e25 (2010).
5. Christensen, N., Søndergaard, J., Christesen, H. T., Fisker, N. & Husby, S. Association
Between Mode of Delivery and Risk of Infection in Early Childhood: A Cohort Study.
The Pediatric Infectious Disease Journal 37, 316–323 (2018).
6. Effect of breastfeeding on infant and child mortality due to infectious diseases in
less developed countries: a pooled analysis. The Lancet 355, 451–455 (2000).
7. Victora, C. G. et al. Breastfeeding in the 21st century: epidemiology, mechanisms,
and lifelong effect. The Lancet 387, 475–490 (2016).
8. Martino, D. & Prescott, S. Epigenetics and Prenatal Influences on Asthma and
Allergic Airways Disease. Chest 139, 640–647 (2011).

104

9. Lack, G. Update on risk factors for food allergy. Journal of Allergy and Clinical
Immunology 129, 1187–1197 (2012).
10. van Neerven, R. J. J. & Savelkoul, H. Nutrition and Allergic Diseases. Nutrients 9, 762
(2017).
11. Risnes, K. R., Belanger, K., Murk, W. & Bracken, M. B. Antibiotic Exposure by 6
Months and Asthma and Allergy at 6 Years: Findings in a Cohort of 1,401 US
Children. American Journal of Epidemiology 173, 310–318 (2011).
12. Kronman, M. P., Zaoutis, T. E., Haynes, K., Feng, R. & Coffin, S. E. Antibiotic Exposure
and IBD Development Among Children: A Population-Based Cohort Study. Pediatrics
130, e794–e803 (2012).
13. Hoskin-Parr, L., Teyhan, A., Blocker, A. & Henderson, A. J. W. Antibiotic exposure in
the first two years of life and development of asthma and other allergic diseases by
7.5 yr: a dose-dependent relationship. Pediatr Allergy Immunol 24, 762–771 (2013).
14. Metsälä, J. et al. Mother’s and Offspring’s Use of Antibiotics and Infant Allergy to
Cow’s Milk. Epidemiology 24, 303–309 (2013).
15. Miller, J. E. et al. Maternal antibiotic exposure during pregnancy and hospitalization
with infection in offspring: a population-based cohort study. International Journal of
Epidemiology 47, 561–571 (2018).
16. Baron, R. et al. The relationship of prenatal antibiotic exposure and infant antibiotic
administration with childhood allergies: a systematic review. BMC Pediatrics 20, 312
(2020).

105

17. Mozaffarian, D. & Rimm, E. B. Fish Intake, Contaminants, and Human Health:
Evaluating the Risks and the Benefits. JAMA 296, 1885–1899 (2006).
18. Järup, L. Hazards of heavy metal contamination. Br Med Bull 68, 167–182 (2003).
19. Williams, P. N. et al. Greatly Enhanced Arsenic Shoot Assimilation in Rice Leads to
Elevated Grain Levels Compared to Wheat and Barley. Environ. Sci. Technol. 41,
6854–6859 (2007).
20. O’Donovan, S. M. et al. Adherence with early infant feeding and complementary
feeding guidelines in the Cork BASELINE Birth Cohort Study. Public Health Nutr 18,
2864–2873 (2015).
21. Karagas, M. R. et al. Association of Rice and Rice-Product Consumption With Arsenic
Exposure Early in Life. JAMA Pediatr 170, 609–616 (2016).
22. Dangleben, N. L., Skibola, C. F. & Smith, M. T. Arsenic immunotoxicity: a review.
Environ Health 12, 73 (2013).
23. Farzan, S. F. et al. Infant Infections and Respiratory Symptoms in Relation to in Utero
Arsenic Exposure in a U.S. Cohort. Environ Health Perspect 124, 840–847 (2016).
24. Signes-Pastor, A. J. et al. Infants’ dietary arsenic exposure during transition to solid
food. Scientific Reports 8, 7114 (2018).
25. Gensollen, T., Iyer, S. S., Kasper, D. L. & Blumberg, R. S. How colonization by
microbiota in early life shapes the immune system. Science 352, 539–544 (2016).
26. Zheng, D., Liwinski, T. & Elinav, E. Interaction between microbiota and immunity in
health and disease. Cell Research 30, 492–506 (2020).

106

27. Coker, M. & Madan, J. C. The microbiome and immune system development. in The
Developing Microbiome 43–66 (Academic Press, 2020).
28. Gaboriau-Routhiau, V. et al. The Key Role of Segmented Filamentous Bacteria in the
Coordinated Maturation of Gut Helper T Cell Responses. Immunity 31, 677–689
(2009).
29. Chung, H. et al. Gut Immune Maturation Depends on Colonization with a HostSpecific Microbiota. Cell 149, 1578–1593 (2012).
30. Umesaki, Y., Setoyama, H., Matsumoto, S., Imaoka, A. & Itoh, K. Differential Roles of
Segmented Filamentous Bacteria and Clostridia in Development of the Intestinal
Immune System. Infection and Immunity 67, 3504–3511 (1999).
31. Schnupf, P., Gaboriau-Routhiau, V. & Cerf-Bensussan, N. Host interactions with
Segmented Filamentous Bacteria: An unusual trade-off that drives the post-natal
maturation of the gut immune system. Seminars in Immunology 25, 342–351 (2013).
32. Atarashi, K. et al. Induction of Colonic Regulatory T Cells by Indigenous Clostridium
Species. Science 331, 337–341 (2011).
33. Tan, T. G. et al. Identifying species of symbiont bacteria from the human gut that,
alone, can induce intestinal Th17 cells in mice. Proc Natl Acad Sci U S A 113, E8141–
E8150 (2016).
34. Sefik, E. et al. Individual intestinal symbionts induce a distinct population of RORγ+
regulatory T cells. Science 349, 993–997 (2015).
35. Round, J. L. & Mazmanian, S. K. The gut microbiome shapes intestinal immune
responses during health and disease. Nat Rev Immunol 9, 313–323 (2009).

107

36. Mazmanian, S. K., Liu, C. H., Tzianabos, A. O. & Kasper, D. L. An immunomodulatory
molecule of symbiotic bacteria directs maturation of the host immune system. Cell
122, 107–118 (2005).
37. Sokol, H. et al. Faecalibacterium prausnitzii is an anti-inflammatory commensal
bacterium identified by gut microbiota analysis of Crohn disease patients. Proc Natl
Acad Sci U S A 105, 16731–16736 (2008).
38. Cervantes-Barragan, L. et al. Lactobacillus reuteri induces gut intraepithelial
CD4+CD8αα+ T cells. Science 357, 806–810 (2017).
39. Das, G. et al. An important regulatory role for CD4+CD8αα T cells in the intestinal
epithelial layer in the prevention of inflammatory bowel disease. PNAS 100, 5324–
5329 (2003).
40. Khosravi, A. et al. Gut microbiota promotes hematopoiesis tocontrol bacterial
infection. Cell Host Microbe 15, 374–381 (2014).
41. Belkaid, Y. & Hand, T. Role of the Microbiota in Immunity and inflammation. Cell
157, 121–141 (2014).
42. Milani, C. et al. The First Microbial Colonizers of the Human Gut: Composition,
Activities, and Health Implications of the Infant Gut Microbiota. Microbiology and
Molecular Biology Reviews (2017) doi:10.1128/MMBR.00036-17.
43. Prince, B. T., Mandel, M. J., Nadeau, K. & Singh, A. M. Gut Microbiome and the
Development of Food Allergy and Allergic Disease. Pediatr Clin North Am 62, 1479–
1492 (2015).

108

44. Cuello-Garcia, C. A. et al. Probiotics for the prevention of allergy: A systematic
review and meta-analysis of randomized controlled trials. Journal of Allergy and
Clinical Immunology 136, 952–961 (2015).
45. Chang, Y.-S. et al. Synbiotics for Prevention and Treatment of Atopic Dermatitis: A
Meta-analysis of Randomized Clinical Trials. JAMA Pediatrics 170, 236–242 (2016).
46. Ren, X. et al. The distribution characteristics of intestinal microbiota in children with
community-acquired pneumonia under five Years of age. Microbial Pathogenesis
142, 104062 (2020).
47. Reyman, M. et al. Impact of delivery mode-associated gut microbiota dynamics on
health in the first year of life. Nature Communications 10, 4997 (2019).
48. Hasegawa, K. et al. The Fecal Microbiota Profile and Bronchiolitis in Infants.
Pediatrics 138, (2016).
49. Huda, M. N. et al. Stool Microbiota and Vaccine Responses of Infants. Pediatrics 134,
e362–e372 (2014).
50. Harris, V. C. et al. Significant Correlation Between the Infant Gut Microbiome and
Rotavirus Vaccine Response in Rural Ghana. The Journal of Infectious Diseases 215,
34–41 (2017).
51. Harris, V. et al. Rotavirus vaccine response correlates with the infant gut microbiota
composition in Pakistan. Gut Microbes 9, 93–101 (2018).
52. Huda, M. N. et al. Bifidobacterium Abundance in Early Infancy and Vaccine Response
at 2 Years of Age. Pediatrics 143, (2019).

109

53. Hasan, N. & Yang, H. Factors affecting the composition of the gut microbiota, and its
modulation. PeerJ 7, e7502 (2019).
54. Claus, S. P., Guillou, H. & Ellero-Simatos, S. The gut microbiota: a major player in the
toxicity of environmental pollutants? npj Biofilms Microbiomes 2, 1–11 (2016).
55. Coryell, M., Roggenbeck, B. A. & Walk, S. T. The Human Gut Microbiome’s Influence
on Arsenic Toxicity. Curr Pharmacol Rep 5, 491–504 (2019).
56. Baldassarre, M. E. et al. Dysbiosis and Prematurity: Is There a Role for Probiotics?
Nutrients 11, 1273 (2019).
57. Depner, M. et al. Maturation of the gut microbiome during the first year of life
contributes to the protective farm effect on childhood asthma. Nat Med 26, 1766–
1775 (2020).
58. Tun, H. M. et al. Roles of Birth Mode and Infant Gut Microbiota in Intergenerational
Transmission of Overweight and Obesity From Mother to Offspring. JAMA Pediatrics
172, 368–377 (2018).
59. Lynn, M. A. et al. Early-Life Antibiotic-Driven Dysbiosis Leads to Dysregulated
Vaccine Immune Responses in Mice. Cell Host & Microbe 23, 653-660.e5 (2018).
60. Gonzalez-Perez, G. et al. Maternal Antibiotic Treatment Impacts Development of the
Neonatal Intestinal Microbiome and Antiviral Immunity. The Journal of Immunology
196, 3768–3779 (2016).
61. Patrick, D. M. et al. Decreasing antibiotic use, the gut microbiota, and asthma
incidence in children: evidence from population-based and prospective cohort
studies. The Lancet Respiratory Medicine 8, 1094–1105 (2020).

110

62. Zeng, P., Shao, Z. & Zhou, X. Statistical methods for mediation analysis in the era of
high-throughput genomics: Current successes and future challenges. Computational
and Structural Biotechnology Journal 19, 3209–3224 (2021).
63. Baron, R. M. & Kenny, D. A. The moderator–mediator variable distinction in social
psychological research: Conceptual, strategic, and statistical considerations. Journal
of Personality and Social Psychology 51, 1173–1182 (1986).
64. MacKinnon, D. P., Lockwood, C. M., Hoffman, J. M., West, S. G. & Sheets, V. A
comparison of methods to test mediation and other intervening variable effects.
Psychol Methods 7, 83–104 (2002).
65. Robins, J. M. & Greenland, S. Identifiability and Exchangeability for Direct and
Indirect Effects. Epidemiology 3, 143–155 (1992).
66. Pearl, J. Direct and indirect effects. in Proceedings of the Seventeenth conference on
Uncertainty in artificial intelligence 411–420 (Morgan Kaufmann Publishers Inc.,
2001).
67. Rubin, D. B. Causal Inference Using Potential Outcomes. Journal of the American
Statistical Association 100, 322–331 (2005).
68. Imai, K. & Yamamoto, T. Identification and Sensitivity Analysis for Multiple Causal
Mechanisms: Revisiting Evidence from Framing Experiments. Political Analysis 21,
141–171 (2013).
69. VanderWeele, T. & Vansteelandt, S. Mediation Analysis with Multiple Mediators.
Epidemiologic Methods 2, 95–115 (2014).

111

70. Huang, Y.-T. & Pan, W.-C. Hypothesis test of mediation effect in causal mediation
model with high-dimensional continuous mediators. Biometrics 72, 402–413 (2016).
71. Chén, O. Y. et al. High-dimensional multivariate mediation with application to
neuroimaging data. Biostatistics 19, 121–136 (2018).
72. Zhang, Q. High-Dimensional Mediation Analysis with Applications to Causal Gene
Identification. Stat Biosci (2021) doi:10.1007/s12561-021-09328-0.
73. Zhao, Y., Lindquist, M. A. & Caffo, B. S. Sparse principal component based highdimensional mediation analysis. Computational Statistics & Data Analysis 142,
106835 (2020).
74. Boca, S. M., Sinha, R., Cross, A. J., Moore, S. C. & Sampson, J. N. Testing multiple
biological mediators simultaneously. Bioinformatics 30, 214–220 (2014).
75. Millstein, J., Chen, G. K. & Breton, C. V. cit: hypothesis testing software for
mediation analysis in genomic applications. Bioinformatics 32, 2364–2365 (2016).
76. Sampson, J. N., Boca, S. M., Moore, S. C. & Heller, R. FWER and FDR control when
testing multiple mediators. Bioinformatics 34, 2418–2424 (2018).
77. Djordjilović, V. et al. Global test for high-dimensional mediation: Testing groups of
potential mediators. Statistics in Medicine 38, 3346–3360 (2019).
78. Liu, Z. et al. Large-Scale Hypothesis Testing for Causal Mediation Effects with
Applications in Genome-wide Epigenetic Studies. Journal of the American Statistical
Association 117, 67–81 (2022).

112

79. Dai, J. Y., Stanford, J. L. & LeBlanc, M. A Multiple-Testing Procedure for HighDimensional Mediation Hypotheses. Journal of the American Statistical Association
117, 198–213 (2022).
80. Gao, Y. et al. Testing Mediation Effects in High-Dimensional Epigenetic Studies.
Frontiers in Genetics 10, (2019).
81. Song, Y. et al. Bayesian shrinkage estimation of high dimensional causal mediation
effects in omics studies. Biometrics 76, 700–710 (2020).
82. Sohn, M. B. & Li, H. Compositional mediation analysis for microbiome studies. The
Annals of Applied Statistics 13, 661–681 (2019).
83. Zhang, J., Wei, Z. & Chen, J. A distance-based approach for testing the mediation
effect of the human microbiome. Bioinformatics 34, 1875–1883 (2018).
84. Wang, C., Hu, J., Blaser, M. J. & Li, H. Estimating and testing the microbial causal
mediation effect with high-dimensional and compositional microbiome data.
Bioinformatics 36, 347–355 (2020).
85. Zhang, H. et al. Mediation effect selection in high-dimensional and compositional
microbiome data. Statistics in Medicine 40, 885–896 (2021).
86. Zhang, H., Chen, J., Li, Z. & Liu, L. Testing for Mediation Effect with Application to
Human Microbiome Data. Stat Biosci 13, 313–328 (2021).
87. Wu, Q. et al. MedZIM: Mediation analysis for Zero-Inflated Mediators with
applications to microbiome data. arXiv:1906.09175 [stat] (2021).
88. Sohn, M. B., Lu, J. & Li, H. A compositional mediation model for a binary outcome:
Application to microbiome studies. Bioinformatics 38, 16–21 (2022).

113

89. Simon, A. K., Hollander, G. A. & McMichael, A. Evolution of the immune system in
humans from infancy to old age. Proc Biol Sci 282, (2015).
90. Holt, P. G. & Jones, C. A. The development of the immune system during pregnancy
and early life. Allergy 55, 688–697 (2000).
91. Global, regional, and national age-sex specific all-cause and cause-specific mortality
for 240 causes of death, 1990-2013: a systematic analysis for the Global Burden of
Disease Study 2013. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4340604/.
92. Mennella, J. A., Ziegler, P., Briefel, R. & Novak, T. Feeding Infants and Toddlers
Study: The Types of Foods Fed to Hispanic Infants and Toddlers. Journal of the
American Dietetic Association 106, 96–106 (2006).
93. Meharg, A. A. et al. Inorganic arsenic levels in baby rice are of concern.
Environmental Pollution 152, 746–749 (2008).
94. Lai, P. Y., Cottingham, K. L., Steinmaus, C., Karagas, M. R. & Miller, M. D. Arsenic and
Rice: Translating Research to Address Health Care Providers’ Needs. J Pediatr 167,
797–803 (2015).
95. Zhao, F.-J., McGrath, S. P. & Meharg, A. A. Arsenic as a Food Chain Contaminant:
Mechanisms of Plant Uptake and Metabolism and Mitigation Strategies. Annual
Review of Plant Biology 61, 535–559 (2010).
96. Punshon, T. et al. Understanding arsenic dynamics in agronomic systems to predict
and prevent uptake by crop plants. Science of The Total Environment 581–582, 209–
220 (2017).

114

97. US EPA. Monosodium Methanearsonate (MSMA), an Organic Arsenical. US EPA
https://www.epa.gov/ingredients-used-pesticide-products/monosodiummethanearsonate-msma-organic-arsenical (2015).
98. Dickens, R. & Hiltbold, A. E. Movement and Persistence of Methanearsonates in Soil.
Weeds 15, 299–304 (1967).
99. U.S. FDA. FDA Makes Available Results from Testing of Infant Rice Cereal for
Inorganic Arsenic. FDA http://www.fda.gov/food/cfsan-constituent-updates/fdamakes-available-results-testing-infant-rice-cereal-inorganic-arsenic (2020).
100.

Naujokas, M. F. et al. The Broad Scope of Health Effects from Chronic Arsenic

Exposure: Update on a Worldwide Public Health Problem. Environ Health Perspect
121, 295–302 (2013).
101.

Ahmed, S. et al. In Utero Arsenic Exposure Is Associated With Impaired Thymic

Function in Newborns Possibly Via Oxidative Stress and Apoptosis. Toxicol Sci 129,
305–314 (2012).
102.

Tregoning, J. S. & Schwarze, J. Respiratory Viral Infections in Infants: Causes,

Clinical Symptoms, Virology, and Immunology. Clinical Microbiology Reviews 23, 74–
98 (2010).
103.

Rahman, A., Vahter, M., Ekström, E.-C. & Persson, L.-Å. Arsenic Exposure in

Pregnancy Increases the Risk of Lower Respiratory Tract Infection and Diarrhea
during Infancy in Bangladesh. Environmental Health Perspectives 119, 719–724
(2011).

115

104.

Raqib, R. et al. Effects of in utero arsenic exposure on child immunity and

morbidity in rural Bangladesh. Toxicol. Lett. 185, 197–202 (2009).
105.

Winterbottom, E. F. et al. Prenatal arsenic exposure alters the placental

expression of multiple epigenetic regulators in a sex-dependent manner.
Environmental Health 18, 18 (2019).
106.

Nygaard, U. C. et al. Cord blood T cell subpopulations and associations with

maternal cadmium and arsenic exposures. PLOS ONE 12, e0179606 (2017).
107.

Hoen, A. G. et al. Sex-specific associations of infants’ gut microbiome with

arsenic exposure in a US population. Scientific Reports 8, 12627 (2018).
108.

Nadeau, K. C. et al. In utero arsenic exposure and fetal immune repertoire in a

US pregnancy cohort. Clin Immunol 155, 188–197 (2014).
109.

Belderbos, M., Levy, O. & Bont, L. Neonatal innate immunity in allergy

development. Current Opinion in Pediatrics 21, 762–769 (2009).
110.

Martino, D. J. & Prescott, S. L. Silent mysteries: epigenetic paradigms could hold

the key to conquering the epidemic of allergy and immune disease. Allergy 65, 7–15
(2010).
111.

Deo, S. S., Mistry, K. J., Kakade, A. M. & Niphadkar, P. V. Role played by Th2 type

cytokines in IgE mediated allergy and asthma. Lung India 27, 66–71 (2010).
112.

Smith, A. H. et al. Chronic respiratory symptoms in children following in utero

and early life exposure to arsenic in drinking water in Bangladesh. Int J Epidemiol 42,
1077–1086 (2013).

116

113.

George, C. M. et al. Arsenic exposure is associated with pediatric pneumonia in

rural Bangladesh: a case control study. Environ Health 14, (2015).
114.

Karagas, M. R. et al. Rice Intake and Emerging Concerns on Arsenic in Rice: a

Review of the Human Evidence and Methodologic Challenges. Curr Envir Health Rpt
(2019) doi:10.1007/s40572-019-00249-1.
115.

European Food Safety Authority. Dietary exposure to inorganic arsenic in the

European population. EFSA Journal 12, 3597 (2014).
116.

Commission Regulation (EU) 2015/1006 of 25 June 2015 amending Regulation

(EC) No 1881/2006 as regards maximum levels of inorganic arsenic in foodstuffs
(Text with EEA relevance). OJ L vol. 161 (2015).
117.

U.S. FDA. FDA proposes limit for inorganic arsenic in infant rice cereal. FDA

http://www.fda.gov/news-events/press-announcements/fda-proposes-limitinorganic-arsenic-infant-rice-cereal (2016).
118.

Food Safety: Federal Efforts to Manage the Risk of Arsenic in Rice.

https://www.gao.gov/assets/700/690701.pdf (2018).
119.

U.S. FDA. A Quantitative Assessment of Inorganic Arsenic in Apple Juice. (2013).

120.

US EPA, O. National Primary Drinking Water Regulations. US EPA

https://www.epa.gov/ground-water-and-drinking-water/national-primary-drinkingwater-regulations (2015).
121.

NJDEP-News Release 04/130 - DEP Adopts New Mercury, Arsenic Standards.

https://www.nj.gov/dep/newsrel/2004/04_0130.htm.

117

122.

New Hampshire HB261 | 2019 | Regular Session. LegiScan

https://legiscan.com/NH/text/HB261/id/1964222.
123.

Gilbert-Diamond, D. et al. Rice consumption contributes to arsenic exposure in

US women. Proc Natl Acad Sci U S A 108, 20656–20660 (2011).
124.

Madan, J. C. et al. Association of Cesarean Delivery and Formula

Supplementation With the Intestinal Microbiome of 6-Week-Old Infants. JAMA
Pediatr 170, 212 (2016).
125.

Carignan, C. C. et al. Estimated Exposure to Arsenic in Breastfed and Formula-Fed

Infants in a United States Cohort. Environ Health Perspect 123, 500–506 (2015).
126.

Zou, G. & Donner, A. Extension of the modified Poisson regression model to

prospective studies with correlated binary data. Stat Methods Med Res 22, 661–670
(2013).
127.

White, I. R., Royston, P. & Wood, A. M. Multiple imputation using chained

equations: Issues and guidance for practice. Statistics in Medicine 30, 377–399
(2011).
128.

Yorita, K. L., Holman, R. C., Sejvar, J. J., Steiner, C. A. & Schonberger, L. B.

Infectious disease hospitalizations among infants in the United States. Pathologica
121, 244–252 (2008).
129.

Jackson, K. D., Howie, L. D. & Akinbami, L. J. Trends in allergic conditions among

children: United States, 1997-2011. NCHS Data Brief 1–8 (2013).
130.

National Center for Health Statistics. Allergies and Hay Fever. Centeror Disease

Control and Prevention https://www.cdc.gov/nchs/fastats/allergies.htm (2019).

118

131.

Wilson, A. C. et al. Relation of infant diet to childhood health: seven year follow

up of cohort of children in Dundee infant feeding study. BMJ 316, 21–25 (1998).
132.

Wright, C. M., Parkinson, K. N. & Drewett, R. F. Why are babies weaned early?

Data from a prospective population based cohort study. Archives of Disease in
Childhood 89, 813–816 (2004).
133.

Poole, J. A. et al. Timing of Initial Exposure to Cereal Grains and the Risk of

Wheat Allergy. Pediatrics 117, 2175–2182 (2006).
134.

Bellamri, N., Morzadec, C., Fardel, O. & Vernhet, L. Arsenic and the immune

system. Current Opinion in Toxicology 10, 60–68 (2018).
135.

World Health Organization. Guidelines for Drinking-Water Quality. (1993).

136.

World Health Organization. Preventing disease through healthy environments:

exposure to arsenic: a major public health concern. (2019).
137.

Signes-Pastor, A. J. et al. Levels of infants’ urinary arsenic metabolites related to

formula feeding and weaning with rice products exceeding the EU inorganic arsenic
standard. PLoS One 12, (2017).
138.

U.S. FDA. Arsenic in Rice and Rice Products Risk Assessment Report.

https://www.fda.gov/media/96071/download (2016).
139.

Korioth, T. Parent Plus: Limit infants’ exposure to arsenic by feeding a variety of

grains. AAP News (2019).
140.

Islam, S., Rahman, M. M., Islam, M. R. & Naidu, R. Arsenic accumulation in rice:

Consequences of rice genotypes and management practices to reduce human health
risk. Environment International 96, 139–155 (2016).

119

141.

Cubadda, F., Jackson, B. P., Cottingham, K. L., Van Horne, Y. O. & Kurzius-

Spencer, M. Human exposure to dietary inorganic arsenic and other arsenic species:
State of knowledge, gaps and uncertainties. Sci Total Environ 579, 1228–1239
(2017).
142.

Lozano, R. et al. Global and regional mortality from 235 causes of death for 20

age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease
Study 2010. The Lancet 380, 2095–2128 (2012).
143.

Wang, Y. et al. 16S rRNA gene-based analysis of fecal microbiota from preterm

infants with and without necrotizing enterocolitis. The ISME Journal 3, 944–954
(2009).
144.

Antosca, K. M. et al. Altered Stool Microbiota of Infants with Cystic Fibrosis

Shows a Reduction in Genera Associated with Immune Programming from Birth.
Journal of Bacteriology 201, (2019).
145.

Hoen, A. G. et al. Associations between Gut Microbial Colonization in Early Life

and Respiratory Outcomes in Cystic Fibrosis. The Journal of Pediatrics 167, 138147.e3 (2015).
146.

Stewart, C. J. et al. The preterm gut microbiota: changes associated with

necrotizing enterocolitis and infection. Acta Paediatrica 101, 1121–1127 (2012).
147.

Stewart, C. J. et al. Longitudinal development of the gut microbiome and

metabolome in preterm neonates with late onset sepsis and healthy controls.
Microbiome 5, 75 (2017).

120

148.

Jakobsson, H. E. et al. Decreased gut microbiota diversity, delayed Bacteroidetes

colonisation and reduced Th1 responses in infants delivered by Caesarean section.
Gut 63, 559–566 (2014).
149.

Bäckhed, F. et al. Dynamics and Stabilization of the Human Gut Microbiome

during the First Year of Life. Cell Host & Microbe 17, 690–703 (2015).
150.

Schwartz, S. et al. A metagenomic study of diet-dependent interaction between

gut microbiota and host in infants reveals differences in immune response. Genome
Biology 13, r32 (2012).
151.

Bosch, A. A. T. M. et al. Development of Upper Respiratory Tract Microbiota in

Infancy is Affected by Mode of Delivery. EBioMedicine 9, 336–345 (2016).
152.

Laubereau, B. et al. Caesarean section and gastrointestinal symptoms, atopic

dermatitis, and sensitisation during the first year of life. Archives of Disease in
Childhood 89, 993–997 (2004).
153.

Dieterich, C. M., Felice, J. P., O’Sullivan, E. & Rasmussen, K. M. Breastfeeding and

Health Outcomes for the Mother-Infant Dyad. Pediatr Clin North Am 60, 31–48
(2013).
154.

Zhang, M. et al. Association of prenatal antibiotics with measures of infant

adiposity and the gut microbiome. Ann Clin Microbiol Antimicrob 18, 18 (2019).
155.

Zou, Z.-H. et al. Prenatal and postnatal antibiotic exposure influences the gut

microbiota of preterm infants in neonatal intensive care units. Ann Clin Microbiol
Antimicrob 17, 9 (2018).

121

156.

Coker, M. et al. Specific class of intrapartum antibiotics relates to maturation of

the infant gut microbiota: a prospective cohort study. BJOG 127, 217–227 (2020).
157.

Hemarajata, P. & Versalovic, J. Effects of probiotics on gut microbiota:

mechanisms of intestinal immunomodulation and neuromodulation. Therap Adv
Gastroenterol 6, 39–51 (2013).
158.

Tamburini, S., Shen, N., Wu, H. C. & Clemente, J. C. The microbiome in early life:

implications for health outcomes. Nat Med 22, 713–722 (2016).
159.

Harding, J. N. et al. Altered gut microbiota in infants is associated with

respiratory syncytial virus disease severity. BMC Microbiology 20, 140 (2020).
160.

Lundgren, S. N. et al. Maternal diet during pregnancy is related with the infant

stool microbiome in a delivery mode-dependent manner. Microbiome 6, 109 (2018).
161.

Callahan, B. J. et al. DADA2: High-resolution sample inference from Illumina

amplicon data. Nature Methods 13, 581–583 (2016).
162.

Pruesse, E. et al. SILVA: a comprehensive online resource for quality checked and

aligned ribosomal RNA sequence data compatible with ARB. Nucleic Acids Res 35,
7188–7196 (2007).
163.

McIver, L. J. et al. bioBakery: a meta’omic analysis environment. Bioinformatics

34, 1235–1237 (2018).
164.

Segata, N. et al. Metagenomic microbial community profiling using unique clade-

specific marker genes. Nature Methods 9, 811–814 (2012).
165.

Li, J. & Ji, L. Adjusting multiple testing in multilocus analyses using the

eigenvalues of a correlation matrix. Heredity 95, 221–227 (2005).

122

166.

Rosas-Salazar, C. et al. Exclusive Breastfeeding, the Early-life Microbiome and

Immune Response, and Common Childhood Respiratory Illnesses. Journal of Allergy
and Clinical Immunology 0, (2022).
167.

Poppleton, D. I. et al. Outer Membrane Proteome of Veillonella parvula: A

Diderm Firmicute of the Human Microbiome. Frontiers in Microbiology 8, (2017).
168.

Reichardt, N. et al. Phylogenetic distribution of three pathways for propionate

production within the human gut microbiota. ISME J 8, 1323–1335 (2014).
169.

Shimizu, J. et al. Propionate-producing bacteria in the intestine may associate

with skewed responses of IL10-producing regulatory T cells in patients with
relapsing polychondritis. PLoS One 13, (2018).
170.

van den Bogert, B., Meijerink, M., Zoetendal, E. G., Wells, J. M. & Kleerebezem,

M. Immunomodulatory Properties of Streptococcus and Veillonella Isolates from the
Human Small Intestine Microbiota. PLoS One 9, (2014).
171.

Yang, K., Kruse, R. L., Lin, W. V. & Musher, D. M. Corynebacteria as a cause of

pulmonary infection: a case series and literature review. Pneumonia 10, 10 (2018).
172.

Manzella, J. P., Kellogg, J. A. & Parsey, K. S. Corynebacterium

pseudodiphtheriticum : A Respiratory Tract Pathogen in Adults. Clinical Infectious
Diseases 20, 37–40 (1995).
173.

Ahmed, K. et al. Corynebacterium pseudodiphtheriticum: A Respiratory Tract

Pathogen. Clinical Infectious Diseases 20, 41–46 (1995).

123

174.

Edouard, S. et al. The nasopharyngeal microbiota in patients with viral

respiratory tract infections is enriched in bacterial pathogens. Eur J Clin Microbiol
Infect Dis 37, 1725–1733 (2018).
175.

Hayashi, A. et al. A single strain of Clostridium butyricum induces intestinal IL-10-

producing macrophages to suppress acute experimental colitis in mice. Cell Host
Microbe 13, 711–722 (2013).
176.

Atarashi, K. et al. T reg induction by a rationally selected mixture of Clostridia

strains from the human microbiota. Nature 500, 232–236 (2013).
177.

Lozupone, C. et al. Identifying genomic and metabolic features that can underlie

early successional and opportunistic lifestyles of human gut symbionts. Genome Res.
22, 1974–1984 (2012).
178.

Mégraud, F., Bébéar, C., Dabernat, H. & Delmas, C. Haemophilus species in the

human gastrointestinal tract. Eur. J. Clin. Microbiol. Infect. Dis. 7, 437–438 (1988).
179.

Zhang, D. et al. The Cross-Talk Between Gut Microbiota and Lungs in Common

Lung Diseases. Front Microbiol 11, 301 (2020).
180.

Yang, I. et al. The Infant Microbiome: Implications for Infant Health and

Neurocognitive Development. Nursing Research 65, 76–88 (2016).
181.

Arrieta, M.-C. et al. Associations between infant fungal and bacterial dysbiosis

and childhood atopic wheeze in a nonindustrialized setting. J. Allergy Clin. Immunol.
142, 424-434.e10 (2018).
182.

Arrieta, M.-C. et al. Early infancy microbial and metabolic alterations affect risk

of childhood asthma. Sci Transl Med 7, 307ra152 (2015).

124

183.

Stiemsma, L. T. et al. Shifts in Lachnospira and Clostridium sp. in the 3-month

stool microbiome are associated with preschool age asthma. Clinical Science 130,
2199–2207 (2016).
184.

Abrahamsson, T. R. et al. Low gut microbiota diversity in early infancy precedes

asthma at school age. Clin. Exp. Allergy 44, 842–850 (2014).
185.

Krishnamoorthy, S., Coetzee, V., Kruger, J., Potgieter, H. & Buys, E. M. Dysbiosis

Signatures of Fecal Microbiota in South African Infants with Respiratory,
Gastrointestinal, and Other Diseases. The Journal of Pediatrics 218, 106-113.e3
(2020).
186.

Liu, H. et al. Diagnosing and tracing the pathogens of infantile infectious diarrhea

by amplicon sequencing. Gut Pathogens 11, 12 (2019).
187.

Pop, M. et al. Diarrhea in young children from low-income countries leads to

large-scale alterations in intestinal microbiota composition. Genome Biology 15, R76
(2014).
188.

Monira, S. et al. Metagenomic profile of gut microbiota in children during

cholera and recovery. Gut Pathog 5, 1–9 (2013).
189.

Kaci, G. et al. Anti-Inflammatory Properties of Streptococcus salivarius, a

Commensal Bacterium of the Oral Cavity and Digestive Tract. Appl Environ Microbiol
80, 928–934 (2014).
190.

Achievements in Public Health, 1900-1999 Impact of Vaccines Universally

Recommended for Children -- United States, 1990-1998.
https://www.cdc.gov/mmwr/preview/mmwrhtml/00056803.htm.

125

191.

Chard, A. N. Routine Vaccination Coverage — Worldwide, 2019. MMWR Morb

Mortal Wkly Rep 69, (2020).
192.

Hill, H. A. Vaccination Coverage by Age 24 Months Among Children Born in 2016

and 2017 — National Immunization Survey-Child, United States, 2017–2019. MMWR
Morb Mortal Wkly Rep 69, (2020).
193.

Zimmermann, P. & Curtis, N. Factors That Influence the Immune Response to

Vaccination. Clinical Microbiology Reviews 32, e00084-18.
194.

Zhang, Y. et al. Composition of the murine gut microbiome impacts humoral

immunity induced by rabies vaccines. Clin Transl Med 10, e161 (2020).
195.

Uchiyama, R., Chassaing, B., Zhang, B. & Gewirtz, A. T. Antibiotic Treatment

Suppresses Rotavirus Infection and Enhances Specific Humoral Immunity. The
Journal of Infectious Diseases 210, 171–182 (2014).
196.

Lamousé-Smith, E. S., Tzeng, A. & Starnbach, M. N. The Intestinal Flora Is

Required to Support Antibody Responses to Systemic Immunization in Infant and
Germ Free Mice. PLOS ONE 6, e27662 (2011).
197.

Oh, J. Z. et al. TLR5-Mediated Sensing of Gut Microbiota Is Necessary for

Antibody Responses to Seasonal Influenza Vaccination. Immunity 41, 478–492
(2014).
198.

Beghini, F. et al. Integrating taxonomic, functional, and strain-level profiling of

diverse microbial communities with bioBakery 3. eLife 10, e65088 (2021).

126

199.

Jódar, L. et al. Serological criteria for evaluation and licensure of new

pneumococcal conjugate vaccine formulations for use in infants. Vaccine 21, 3265–
3272 (2003).
200.

Liang, J. L. Prevention of Pertussis, Tetanus, and Diphtheria with Vaccines in the

United States: Recommendations of the Advisory Committee on Immunization
Practices (ACIP). MMWR Recomm Rep 67, (2018).
201.

Birth-18 Years Immunization Schedule | CDC.

https://www.cdc.gov/vaccines/schedules/hcp/imz/child-adolescent.html (2021).
202.

Olarte, L. & Jackson, M. A. Streptococcus pneumoniae. Pediatrics In Review 42,

349–359 (2021).
203.

McCool, T. L., Harding, C. V., Greenspan, N. S. & Schreiber, J. R. B- and T-Cell

Immune Responses to Pneumococcal Conjugate Vaccines: Divergence between
Carrier- and Polysaccharide-Specific Immunogenicity. Infection and Immunity 67,
4862–4869 (1999).
204.

Genova, G. D., Roddick, J., McNicholl, F. & Stevenson, F. K. Vaccination of human

subjects expands both specific and bystander memory T cells but antibody
production remains vaccine specific. Blood 107, 2806–2813 (2006).
205.

Zhao, T. et al. Influence of gut microbiota on mucosal IgA antibody response to

the polio vaccine. npj Vaccines 5, 1–9 (2020).
206.

Robertson, R. C. et al. The fecal microbiome and rotavirus vaccine

immunogenicity in rural Zimbabwean infants. Vaccine 39, 5391–5400 (2021).

127

207.

Fix, J. et al. Association between Gut Microbiome Composition and Rotavirus

Vaccine Response among Nicaraguan Infants. The American Journal of Tropical
Medicine and Hygiene 102, 213–219 (2019).
208.

Mullié, C. et al. Increased Poliovirus-Specific Intestinal Antibody Response

Coincides with Promotion of Bifidobacterium longum-infantis and Bifidobacterium
breve in Infants: A Randomized, Double-Blind, Placebo-Controlled Trial. Pediatr Res
56, 791–795 (2004).
209.

Kukkonen, K., Nieminen, T., Poussa, T., Savilahti, E. & Kuitunen, M. Effect of

probiotics on vaccine antibody responses in infancy – a randomized placebocontrolled double-blind trial. Pediatric Allergy and Immunology 17, 416–421 (2006).
210.

Licciardi, P. et al. Maternal Supplementation with LGG Reduces Vaccine-Specific

Immune Responses in Infants at High-Risk of Developing Allergic Disease. Frontiers
in Immunology 4, 381 (2013).
211.

Lucas-Hourani, M. et al. Inhibition of Pyrimidine Biosynthesis Pathway

Suppresses Viral Growth through Innate Immunity. PLOS Pathogens 9, e1003678
(2013).
212.

Dimitrova, P. et al. Restriction of De Novo Pyrimidine Biosynthesis Inhibits Th1

Cell Activation and Promotes Th2 Cell Differentiation. The Journal of Immunology
169, 3392–3399 (2002).
213.

Hubler, M. J. & Kennedy, A. J. Role of lipids in the metabolism and activation of

immune cells. The Journal of Nutritional Biochemistry 34, 1–7 (2016).

128

214.

Milani, C. et al. The First Microbial Colonizers of the Human Gut: Composition,

Activities, and Health Implications of the Infant Gut Microbiota. Microbiology and
Molecular Biology Reviews 81, e00036-17 (2017).
215.

Coker, M. O. et al. Infant Feeding Alters the Longitudinal Impact of Birth Mode

on the Development of the Gut Microbiota in the First Year of Life. Frontiers in
Microbiology 12, (2021).
216.

VanderWeele, T. J. & Vansteelandt, S. Odds Ratios for Mediation Analysis for a

Dichotomous Outcome. American Journal of Epidemiology 172, 1339–1348 (2010).
217.

Valeri, L. & Vanderweele, T. J. Mediation analysis allowing for exposure-mediator

interactions and causal interpretation: theoretical assumptions and implementation
with SAS and SPSS macros. Psychol Methods 18, 137–150 (2013).
218.

VanderWeele, T. J. A unification of mediation and interaction: a four-way

decomposition. Epidemiology 25, 749–761 (2014).
219.

Tchetgen Tchetgen, E. J. Inverse Odds Ratio-Weighted Estimation for Causal

Mediation Analysis. Stat Med 32, 4567–4580 (2013).
220.

Nguyen, Q. C., Osypuk, T. L., Schmidt, N. M., Glymour, M. M. & Tchetgen

Tchetgen, E. J. Practical Guidance for Conducting Mediation Analysis With Multiple
Mediators Using Inverse Odds Ratio Weighting. American Journal of Epidemiology
181, 349–356 (2015).
221.

Sobel, M. E. Asymptotic Confidence Intervals for Indirect Effects in Structural

Equation Models. Sociological Methodology 13, 290–312 (1982).

129

222.

Egozcue, J. J., Pawlowsky-Glahn, V., Mateu-Figueras, G. & Barceló-Vidal, C.

Isometric Logratio Transformations for Compositional Data Analysis. Mathematical
Geology 35, 279–300 (2003).
223.

McInnes, L., Healy, J. & Melville, J. UMAP: Uniform Manifold Approximation and

Projection for Dimension Reduction. arXiv:1802.03426 [cs, stat] (2020).
224.

Ma, S. et al. A statistical model for describing and simulating microbial

community profiles. PLOS Computational Biology 17, e1008913 (2021).
225.

Dierikx, T. H. et al. The influence of prenatal and intrapartum antibiotics on

intestinal microbiota colonisation in infants: A systematic review. Journal of
Infection 81, 190–204 (2020).

130

